ORIGINAL RESEARCH

OPEN ACCESS

Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma

Chaoqi Zhang^a*, Zhihui Zhang^a*, Nan Sun^a*, Zhen Zhang^b, Guochao Zhang^a, Feng Wang^a, Yuejun Luo^a, Yun Che^a, and Jie He^a

^aDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ^bBiotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

ABSTRACT

Background: Costimulatory molecules play significant roles in mounting anti-tumor immune responses, and antibodies targeting these molecules are recognized as promising adjunctive cancer immunotherapies. Here, we aim to conduct a first full-scale exploration of costimulatory molecules from the B7-CD28 and TNF families in patients with lung adenocarcinoma (LUAD) and generated a costimulatory molecule-based signature (CMS) to predict survival and response to immunotherapy.

Methods: We enrolled 1549 LUAD cases across 10 different cohorts and included 502 samples from TCGA for discovery. The validation set included 970 cases from eight different Gene Expression Omnibus (GEO) datasets and 77 frozen tumor tissues with qPCR data. The underlying mechanisms and predictive immunotherapy capabilities of the CMS were also explored.

Results: A five gene-based CMS (CD40LG, TNFRSF6B, TNFSF13, TNFRSF13C, and TNFRSF19) was initially constructed using the bioinformatics method from TCGA that classifies cases as high- vs. low-risk groups per OS. Multivariable Cox regression analysis confirmed that the CMS was an independent prognostic factor. As expected, CMS exhibited prognostic significance in the stratified cohorts and different validation cohorts. Additionally, the prognostic meta-analysis revealed that CMS was superior to the previous signature. Samples in high- and low-risk groups exhibited significantly different tumor-infiltrating leukocytes and inflammatory activities. Importantly, we found that the CMS scores were closely related to multiple immunotherapy biomarkers.

Conclusion: We conducted the first and most comprehensive costimulatory molecule landscape analysis of patients with LUAD and built a clinically feasible CMS for prognosis and immunotherapy response prediction, which will be helpful for further optimize immunotherapies for cancer.

Background

Over the last few years, lung cancer has become the most common malignant tumor and is a grave danger to global human health, with an annual incidence increasing at a rate of 7.5%.¹ Approximately four out of five lung cancers are classified as non-small cell lung cancer (NSCLC). As the major histological subtype of NSCLC, lung adenocarcinoma (LUAD) accounts for over 1 million worldwide deaths annually.² Despite the amplification of traditional approaches which - in combination with targeted therapy – have reduced mortality, the five-year OS (OS) rate of LUAD remains about 15%.³ The introduction of immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1), has revolutionized lung cancer treatment.^{4,5} More recently, pembrolizumab monotherapy was approved to replace chemotherapy as the frontline treatment for patients with PD-L1 positive metastatic NSCLC.⁶ Although treatment for lung cancer has been improved with the development of ICI-based immunotherapies, only a small

proportion of patients with lung cancer can benefit from this schedule. Therefore, we must be able to predict the best candidates for immunotherapy and develop other novel immune checkpoint targets.

The success of ICIs has emerged from a deep understanding of the functions of the immune system and immunosuppressive conditions that are generated in the tumor microenvironment (TME).^{7,8} In the TME, T cells help distinguish cancer cells from healthy cells and initiate subsequent attacks. Before the attack, the naïve T cells need two signals to be active. The first signal is generated once a specific antigen is recognized by the T cell receptor (TCR). The second signal is a nonspecific costimulatory signal.⁹ Based on the fact that the naïve T cells cannot be activated in without costimulatory signals,¹⁰ cancer cells prevent the recognition of these signals by changing the costimulatory molecule signals and expressions in the TME.¹¹ Hence, ICIs prevent tumor cells from delivering incorrect messages to T cells, thereby selectively restoring a tumorinduced immune deficiency in the TME.¹² In addition to the

CONTACT Jie He prof.jiehe@gmail.com Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

*These authors contributed equally to this work.

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ARTICLE HISTORY

Received 24 April 2020 Revised 14 September 2020 Accepted 14 September 2020

KEYWORDS

Lung cancer; immunotherapy; immune checkpoint; b7-CD28; tnf



Supplemental data for this article can be accessed on the publisher's website.

best described immune checkpoint pathways (PD-L1/PD-1, CD86/CTLA4) that belong to the B7-CD28 family,^{13,14} other co-stimulation pathways mainly arise from the tumor necrosis factor (TNF) family.¹⁵

Currently, 13 molecules are classified as B7-CD28 family members, including eight molecules (CD80, CD86, PD-L1, PD-L2, ICOSLG, B7-H3, B7x, and HHLA2) that belong to the B7 family and five molecules (CD28, CTLA4, ICOS, PD-1, and TMIGD2) that belong to the CD28 family.¹³ The TNF family consists of the TNF ligand superfamily (TNFSF) and the TNF receptor superfamily (TNFRSF) with 48 molecules.¹⁶ Nineteen legends were defined as TNFSF, and other 29 receptors considered members of the TNFRSF (Table 1). These costimulatory molecules - consisting of members of the B7-CD28 and TNF families - constitute potential molecular targets for the development of novel ICIs and may make excellent additions to existing immunotherapeutic strategies.^{17,18} However, the expression patterns and clinical significance of the majority of these members remain unknown. There is a need for full-scale investigations of these molecules in patients with LUAD.

We used LUAD gene expression data from The Cancer Genome Atlas (TCGA) to systematically explore the expression patterns and prognoses of these costimulatory molecules. Then, through a series of statistical methods, we built a costimulatory molecule-based signature (CMS) with significantly different prognoses. The CMS was well-validated in nine different cohorts from Gene Expression Omnibus (GEO) datasets and an independent cohort using clinical samples. Also, according to a prognostic meta-analysis, we determined that CMS was superior to the previous costimulatory molecule-related model. We also found that the CMS was characterized by distinct inflammatory profiles and specific immune infiltrating lymphocytes. What's more, the CMS was able to predict the immunotherapy response in patients with LUAD. Therefore, our work describes the systemic landscape of costimulatory molecules based on B7-CD28 and TNF families and highlights the potential underlying clinical applications for the CMS, thereby supporting the development of rationales to guide prognosis management and immunotherapy in patients with LUAD.

Materials and methods

mRNA expression datasets and clinical information

A total of nine public datasets, including 1472 cases with corresponding mRNA expression data and clinical data, were gathered in this study. The training set consisted of data from 502 patients with genetic information (Illumina HiSeq 2000, log2 transformed RSEM normalized read count) and matching OS data from TCGA that were downloaded from the Cancer Genomics Browser of University of California Santa Cruz (UCSC) (https://genomecancer. ucsc.edu).¹⁹ Eight other public datasets with mRNA microarray data were collected from GEO datasets with processed series matrix files (http://www.ncbi.nlm. nih.gov/geo), including GSE11969 (n = 91, log10 ratio (Cy5/ Cy3) normalized read count),²⁰ GSE13213 (n = 117, log10 ratio (Cy5/Cy3) normalized read count),²¹ GSE19188 (n = 40, log2 transformed RMA normalized read count),²² GSE30219 (n = 83, log2 transformed RMA normalized read count),²³ GSE31210 (n = 226, log2 transformed RMA normalized read count),²⁴ GSE37745 (n = 106, log2 transformed RMA normalized read count),²⁵ GSE41271 (n = 180, log2 transformed RMA normalized read count),²⁶ and GSE50081 (n = 127, log2 transformed RMA normalized read count).²⁷ Moreover, for the genes with one more probe, mean expression values were recognized as the expression data. The clinical characteristics of these patients from multiple institutions are summarized in Table 2.

RNA extraction and quantitative real-time reverse transcription–PCR

We used 77 surgically resected LUAD tissues, collected from The First Affiliated Hospital of Zhengzhou University between August 2013 and January 2015, as the independent cohort. Then total RNA was extracted from LUAD tissues using the RNAiso Plus reagent (Takara, #9109) according to the manufacturer's instructions. The first strand of complementary DNA was synthesized from total RNA using the Prime Script[™] RT reagent kit (Takara, #RR047A). Quantitative real-time PCR was performed with SYBR Premix Ex Taq II (Takara, #RR820A), and data were analyzed in the Agilent Mx3005P. With the endogenous control for normalization of GAPDH, the expression data of all the selected genes were log2 transformed before signature validation. All the primer sequences in this research are displayed in Supplementary Table 1. All patients were received and signed the informed consents. The samples used in the study were approved by the Institutional Review Boards of the First Affiliated Hospital of Zhengzhou University.

Functional enrichment analysis

After deleting the genes with low expression values (more than half of all genes analyzed had 0 expression), functional enrichment analysis based on CMS related genes were conducted through the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) in DAVID 6.8 (http://david.abcc.ncifcrf.gov).

Estimated the profiling of immune cell infiltration

The FPKM of mRNAseq data of LUAD from TCGA was used for estimating the fractions of 22 immune cell types in the TME by CIBERSORT.²⁸ The data was not standardized and genes with mean expression 0 were filtered out before submitting to CIBERSORT. The profiling of multiple immune cell types was performed through the leucocyte gene signature matrix, termed LM22, for the CIBERSORT software (http://cibersort.stanford. edu/). LM22 consists of 547 genes that can distinguish 22 immune cells, including different subtypes of B cell types, T cell types, natural killer cells (NKs), plasma cells, and myeloid cell types.

Biomarkers for predicting immunotherapy response

The potential immunotherapy response prediction performance of CMS was estimated with the following biomarkers: tumor mutation burden (TMB), neoantigen, PD-L1 protein

Table 1. Univariate Cox analysis of costimulatory molecule genes in TCGA Cohort.

CD27 TMFRSF 7 TMFRSF 0.862 0.7858.0.9592 0.0025 CD274 PD-L1, 57-H1 B7 1.0125 0.0239-H1097 0.07897 CD276 B7-H3 B7 1.3865 1.0721-0.9585 0.0102 CD40 TMFRSF 0.020 TMFRSF 0.0883 0.0372-1.10985 0.0102 CD40 TMFRSF 0.021 TMFRSF 0.0888 0.03971-1103 0.1522 CD70 TMFRSF 0.022 D.8878 0.03876-03969 0.0225 CD80 B7-1.C028.G1 B7 0.9999 0.0371-1103 0.1522 CD86 B7-2.C028.G2 B7 0.9999 0.0372-1.0274 0.3345 EDA EDA A.11 <eda-2< td=""> TMFRSF 0.9107 0.3387-0.9888 0.0227 FDA EDA TMFRSF 0.9910 0.0374-1.1154 0.0227 FAS TMFRSF 0.9910 0.3385 1.0252 0.0271 MFRSF 0.9910 0.3385 1.0256 0.0411 MMCS PAHS D.9951 0.0428 0.9979 0.0281</eda-2<>	Official symbol	Aliases	Family	HR	95%CI	P value
CD274 PD-L1, 87-H1 87 1.0125 0.0238-1.1097 0.783 CD226 B7-H3 B7 1.3865 1.0728-1.1979 0.0125 CD28 TP-H4 CD28 0.8863 0.0721-1.49058 0.01125 CD40 TMFRF513, CD40L TMFSF 0.9089 0.0603-1.0246 0.1182 CD40 TMFSF, CD54, CD40L TMFSF 0.1819 0.2771-1.0498 0.0250 CD66 B7-2, CD28LG2 E7 0.9999 0.9074-1.052 0.1252 CD86 B7-2, CD28LG2 E7 0.9999 0.8387-0.9888 0.0259 CD14 CD152 CD28 0.8772 0.974-0.174 0.3355 EDAR EDAA, 1R TMFSF 1.0425 0.974-1.1154 0.2259 EDAR EDAA, 1R TMFSF 0.9063 0.8387-0.9984 0.0259 EDAR TMFSF, CD95 TMFSF 0.9071 0.8397-0.9042 0.0345 EDAX TMFSF, CD95 TMFSF 0.9071 0.9071-0.9042 0.9041	CD27	TNFRSF7	TNFRSF	0.8682	0.7858-0.9592	0.0055
CD276 B7-H3 B7 1.3865 1.0721-0958 0.0102 CD40 TMFRSFS CD40L TMFRSF 0.9089 0.0081-10.246 0.1102 CD40LG TMFRSFS 0.8194 0.7721-0.968 0.0102 CD40LG TMFRSF 0.9089 0.0081-10.246 0.1020 CD70 TMFRSF 0.9089 0.0071-11.999 0.1223 CD70 TMFRSF 0.9099 0.0071-11.999 0.1223 CD74 CD74 CD74 0.9999 0.0071-11.999 0.0345 CD74 CD74 CD74 0.9999 0.0071-11.999 0.0345 EDA CDA A1, EDA A2 TMFRSF 0.9107 0.0387-0.988 0.0227 EDAR EDAR TMFRSF 0.9107 0.0374-0.11154 0.2225 FAS TMFRSF, CD951 TMFRSF 0.9910 0.0374-1.1149 0.0414 FMLQ S7 +12 D.923 0.0841 0.0429 0.0445 LDA TMFRSF D.9107 0.0320-0.9939 <td>CD274</td> <td>PD-L1, B7-H1</td> <td>B7</td> <td>1.0125</td> <td>0.9239-1.1097</td> <td>0.7897</td>	CD274	PD-L1, B7-H1	B7	1.0125	0.9239-1.1097	0.7897
CD28 Tp44 CD28 0.8635 0.7121.9658 0.0182 CD400 TMFRSTS, CD14, CD40L TMFRSF 0.9898 0.0263.1.0246 0.0182 CD70 TMFST, CD14, CD40L TMFSF 0.8849 0.9737.1.1708 0.1522 CD70 TMFST, CD12, CD28, CD CD28 0.9878 0.9784.0.4969 0.0275 CD80 B7.1, CD28, CD CD28 0.9771.1.1708 0.1522 0.0784.0.4969 0.0275 CD44 B7.1, CD28, CD CD28 0.8972 0.0784.0.4969 0.0239 EDA2R TMFRSF, CD95 TMFRSF 0.9671 0.8387.0.9884 0.0239 EDA4 EDA.A1R TMFRSF 0.9631 0.8389.1.0056 0.0444 EDA2R TMFRSF, CD95.1 TMFRSF 0.9603 0.8287.0.9894 0.0341 CD5G D77.4, CD71 TMFRSF 0.9611 0.9602.1.4044 0.9414 ICO5G D728, CVD1 CD28 0.8970 0.8984.0.9994 0.0395 LTA TMFSF1 D.8467 D.774	CD276	B7-H3	B7	1.3865	1.0728-1.7919	0.0125
Ch40. TNFSF b DTMFSF b D0889 D08651.0246 D1125 CD40LG TNFSF, CD27L TNFSF D.848 D.721-0.949 0.0000 CD70 TNFSF, CD27L TNFSF D.868 D.726-0.949 0.0275 CD80 B7-L, CD28LG1 B7 0.877 0.9794-0.9497 0.0116 CD84 B7-Z, CD28LG2 B7 0.9999 0.8727-1.0441 0.313 EDA EDA-AH, EDA-AH, EDA-AH, EDA TNFSF 0.9561 0.8727-1.0441 0.334 EDA TDFSF, CD95. TNFSF 0.9501 0.8727-1.0441 0.3245 FAS TNFSF, CD95. TNFSF 0.9501 0.8296-1.0752 0.814 FAS TNFSF, CD95. TNFSF 0.8027 0.8999-0.9042 0.0361 ICOS CD278, CVID1 CD28 0.8971 0.9961-0.0495 0.0491 ICOS CD278, CVID1 CD28 0.8971 0.991-0.0491 0.8134-0.056 ITR TNFSF 0.8171 0.991-0.0491 0.8134-0.056	CD28	Тр44	CD28	0.8635	0.7721-0.9658	0.0102
CH40LG TNFSF 0.8194 0.721-0.9049 0.0000 CD70 TNFSF, CD22L TNFSF 1.0686 0.757-1.1708 0.1522 CD80 B7-1, CD28LG1 B7 0.9877 0.9799-0.977-1.0211 0.1112 CD44 CD4-4, EDA-4, EDA	CD40	TNFRSF5	TNFRSF	0.9089	0.8063-1.0246	0.1182
CD70 TNFSF7, CD27L TNFSF L0688 0.9757-1.1708 0.1522 CD80 B71, CD28LG1 B7 0.9999 0.8976-1.0252 0.1210 CD86 B72, CD28LG2 B7 0.9999 0.8976-1.0252 0.1210 CD44 CD152 CD28 0.7272 0.724-0.9711 0.0316 EDAA EDA-A1, EDA-A2 TNFSF 0.9561 0.8370-0.9888 0.0229 EDAR EDA-A1, EDA-A2 TNFSF 0.9561 0.83870-0.9888 0.0229 EDAR EDA-A1, EDA-A2 TNFSF 0.9561 0.83970-0.93984 0.0229 EDAR EDA-A1, EDA-A2 TNFSF 0.9801 0.93621-0.056 0.0414 CD3G CD27, CVD1 CD28 0.8970 0.8902-0.9942 0.0484 ICOSG CD27, CVD1 CD28 0.8970 0.8902-0.9942 0.0444 ICOSG CD27, CD27, TNFSF 0.8497 0.7049-0.9050 0.04957 0.0491 ICAS CD27, CD27, TNFSF 0.8497 0.7049-0.90561 0.8991 </td <td>CD40LG</td> <td>TNFSF5, CD154, CD40L</td> <td>TNFSF</td> <td>0.8194</td> <td>0.7421-0.9049</td> <td>0.0000</td>	CD40LG	TNFSF5, CD154, CD40L	TNFSF	0.8194	0.7421-0.9049	0.0000
CB80 B7-1 CD281 B7 D8878 D.7986-0.9696 D.0275 CD86 B7-2 CD28 D8772 D.7924-0.9711 0.0116 CTLA4 CD152 CD28 D.8772 D.7924-0.9711 0.0116 EDA EDA-A1, EDA-A2 TNFRSF D.9107 D.8387-0.9888 0.0229 EDAR EDA-A1, EDA-A2 TNFRSF D.9107 D.8387-0.9888 0.0229 FAS TNFRSF, CD95.1 TNFRSF D.9107 D.8387-0.9888 0.0221 FAS TNFRSF, CD95.1 TNFSF D.9010 D.8021-10436 0.9141 H4LA2 E7-45 D101 D.9021-10448 0.9141 0.9162 COSIG GF4-5 D011 D.9021-10448 0.9165 0.9001 D.9001 D.9012 D.9012 D.9011 D.912-1026 D.9011 D.912-1026 D.921 D.9011 D.912-1027 D.9062 D.8095-1058 D.9091 LTB TNFSF16 CD21 TNFRSF D.9011 D.912-10278 D.9625 </td <td>CD70</td> <td>TNFSF7, CD27L</td> <td>TNFSF</td> <td>1.0688</td> <td>0.9757-1.1708</td> <td>0.1522</td>	CD70	TNFSF7, CD27L	TNFSF	1.0688	0.9757-1.1708	0.1522
CD86 87-2, CD8LG2 87 0.9099 0.8076-10252 0.1210 CTL44 CD52 CD28 0.8772 0.7244-09711 0.0152 EDAA EDA-AL TNFSF 0.9561 0.8372-1.0474 0.3345 EDAR EDA-ALR TNFRSF 0.9501 0.8386-10752 0.417 FAS TNFRSFC, CD5-L TNFSF 0.9003 0.8280+1055 0.6411 FAS TNFRSFC, CD5-L TNFSF 0.9003 0.8280+1056 0.6461 ICOSLG CT45, CD5-L TNFSF 0.9003 0.8280+1056 0.6461 ICOSLG CT42, CD275 B7 0.40477 0.7104-0.9996 0.0393 0.0385 LTB TNFSF3 0.8171 0.7984-0.9679 0.0391 0.1315 LTB TNFSF3 0.8171 0.7984-0.9679 0.0393 0.0385 LTB TNFRSF3 0.8171 0.7984-0.9679 0.9331 0.754 0.5544 DFCO1052 CP281 CP271 TNFRSF 0.9591 <td< td=""><td>CD80</td><td>B7-1, CD28LG1</td><td>B7</td><td>0.8878</td><td>0.7986-0.9869</td><td>0.0275</td></td<>	CD80	B7-1, CD28LG1	B7	0.8878	0.7986-0.9869	0.0275
CTLA4 CD 2 CD 28 0.8772 0.7924.09711 0.0116 EDA EDAA1, EDAA2 TNFSF 0.9107 0.3387.0988 0.0259 EDAR EDAAR TNFRSFC, CD95 TNFRSF 0.9251 0.8387.0988 0.0259 FAS TNFRSFC, CD95-L TNFRSF 0.9303 0.8204-10056 0.0641 HHLA2 67-H5 B7 0.0306 0.0602-10448 0.9414 ICOS CD278, CVID1 CD28 0.8970 0.8092-10948 0.0491 ICOS CD278, CVID1 CD28 0.8770 0.0502-10448 0.9414 ICOS CD278, CVID1 CD28 0.86771 0.0714-0.9996 0.0495 LTA TNFSF1 TNFSF 0.8771 1.0591-16.147 0.0123-10986 0.8680 POCD1 PD-1, CD279 CD28 0.8665 0.8693-10.658 0.8430 PDCD1 PD-1, CD279 CD28 0.8625 0.8693 0.8271-10.024 PDCD1 PD-1, CD279 CD28 0.82625	CD86	B7-2, CD28LG2	B7	0.9099	0.8076-1.0252	0.1210
EDA EDA AJ, EDA AJ, TNFSF 0.9561 0.8727-1.0474 0.3345 EDAR EDA AIR TNFRSF 0.0107 0.8387-0.9588 0.0225 FAS TNRFSF, CD95 TNFRSF 0.9031 0.8396-1.0752 0.4176 FAS TNRFSF, CD95 TNFRSF 0.9033 0.8204-1.0056 0.0641 FAS TNRFSF, CD95-L TNFSF 0.9030 0.8020-0.9042 0.8044 ICOSL CD278, CVD1 CD28 0.8970 0.8092-0.9042 0.8044 ICOSL CD278, CVD1 CD28 0.8971 0.7949-0.9679 0.0031 ITB TNFSF13 TNFSF 0.8071 0.7949-0.9679 0.0031 ITB TNFSF3 TNFSF 0.3077 1.0591-16.147 0.1016 NGFR TNFRSF16 CD211 0.912, 60279 CD28 0.925 0.8693-1.0558 0.4630 PDCD116 PD-1, CD279 CD28 0.925 0.8693-1.0554 0.4554 NFGF TNFRSF16 0.325 0.8262	CTLA4	CD152	CD28	0.8772	0.7924-0.9711	0.0116
EDA2R INRRSF27, XEDAR INRRSF 0.9107 0.8387-0.9888 0.0259 EDAR EDA-AIR INRRSF 0.9501 0.8396-10752 0.4176 FAS INRRSF6, CD95-L INRFSF 0.9031 0.8204-10056 0.0641 HHLA2 B7-H5 B7 1.0016 0.9602-10.448 0.9414 ICOS CD278, CVID1 CD28 0.8707 0.0802-10.948 0.0495 ICA INFSF1 INFSF 0.9181 0.0202-0.9942 0.0385 ICA INFSF1 INFSF 0.8771 0.0794-0.9979 0.0091 ITB INRSF3 INFSF 0.8771 1.091-1.6147 0.0123 ICR INRSF10 INRSF1 1.0213 1.0986 0.8080 PDCD1 PD-1.40279 CD28 0.6691 0.8733-10554 0.5544 RELT INRSF10 INRSF10 INRSF10 0.8427 0.9841 0.9432 INRSF10A IRSF12 INRA6 0.2827 1.0242 0.9424 0.945	EDA	EDA-A1, EDA-A2	TNFSF	0.9561	0.8727-1.0474	0.3345
EDAR EDA AIR TNRSF 1.0425 0.9744-11154 0.2275 FAS TNRSF6, CD95 TNRSF 0.9501 0.8306-10752 0.04176 FASLG TNRSF6, CD95-L TNRSF 0.9083 0.8206-10056 0.0641 LCOSLG B74-H5 B7 0.04872 0.7104-0.9996 0.0495 LTA TNRSF1 TNRSF 0.8912 0.8092-0.9992 0.0384 LTA TNRSF1 TNRSF 0.8918 0.8002-0.9939 0.0385 LTB TNRSF1 1.0011 0.9121-1.0499 0.0495 0.0495 LTB TNRSF13 TNRSF 1.3077 1.0591-1.6147 0.0126 DPCD1LG PD-1, CD279 CD28 0.9625 0.8693-1.0638 0.4630 PDCD1LG PD-1, CD279 CD28 0.9259 0.7884-1.0873 0.3477 NIGD2 CD28+ CD28 0.9259 0.7843 0.3477 NIGD2 CD28+ CD28 0.9259 0.8257-1.0024 0.0657 NIR	EDA2R	TNFRSF27, XEDAR	TNFRSF	0.9107	0.8387-0.9888	0.0259
FAS TMRRSFC, CD95 TMRSF 0.9501 0.8396-1.0752 0.4176 FASLG TMRSFC, CD95-L TMRSF 0.9083 0.8320-1.0055 0.0641 HLLA2 B7+B5 B7 1.0016 0.9602-1.0448 0.9414 LCOS CD278, CVID1 CD28 0.8970 0.8992-0.9942 0.0384 LCOS B7+12, CD275 B7 0.8427 0.7104-0.9996 0.0495 LTA TMRSF1 TMRSF 0.8971 0.7949-0.9679 0.0091 LTB TMRSF3 TMRSF 0.8771 0.7949-0.9679 0.0092 LTB TMRSF16, CD271 TMRSF 0.977 0.9784-1.0873 0.3477 MCD2 PO-1, CD279 CD28 0.9259 0.7884-1.0873 0.3477 TMICD2 CD28H CD28 0.9259 0.7884-1.0873 0.3477 TMICD2 CD28H CD28 0.9257 0.0248 0.0365 TMRSF10A TMRAIR3, CD261 TMRSF5 0.0356 0.8789-1.0433 0.0487 <t< td=""><td>EDAR</td><td>EDA-A1R</td><td>TNFRSF</td><td>1.0425</td><td>0.9744-1.1154</td><td>0.2275</td></t<>	EDAR	EDA-A1R	TNFRSF	1.0425	0.9744-1.1154	0.2275
FASLG TMSFFs (D25-L TMSFF 0.9083 0.8204-1.0056 0.0641 ICOS CD278, CVID1 CD28 0.8970 0.8092-0.9942 0.0384 ICOSLG B744, CD275 B7 0.8427 0.7104-0.9996 0.0495 LTA TMFSF1 TMSFF 0.8917 0.7949-0.9579 0.0091 LTB TMFSF3 TMFSF 0.8917 0.7949-0.9579 0.0901 LTBR TMFRST3 TMFRSF 1.3077 1.0591-1.6147 0.0126 NGFR TMFRST6 0.2021 TMFRSF 1.0011 0.9123-1.0966 0.9808 PDCD1 PD-1, CD279 CD28 0.9625 0.86931-1.0658 0.4303 PDC1 ZD276 CD273 B7 0.9691 0.8733-1.0754 0.5544 RELT TMFRST0, CD273 B7 0.9990 0.8227-1.0023 0.9476 TMKD2 CD281 CD28 0.9290 0.8227-1.0024 0.0656 TMFRST0 TMSFS_CD27 TMFRST 0.3554 0.4428	FAS	TNFRSF6, CD95	TNFRSF	0.9501	0.8396-1.0752	0.4176
HHLA2 B7-HS B7 1.0016 0.9602-1.0448 0.9144 ICOS CD278, CVD11 CD28 0.8970 0.8092-0.9942 0.0384 ICOSLG B7-H2, CD275 B7 0.8427 0.7104-0.9996 0.0495 ITA TNFSF1 TNSF 0.8918 0.8020-0.9996 0.0395 ITB TNFSF3 TNFSF 0.8771 0.7949-0.9679 0.0021 ITB TNFRSF13 TNFRF 1.3077 1.0591-1.6147 0.0126 DPCD1 PD-1, CD279 CD28 0.9625 0.6693-1.0658 0.4430 PDCD1 PD-1, CD279 CD28 0.9229 0.8287-1.0024 0.544 RELT TNFRSF10 TNFRSF1 TNSF5 0.9098 0.8257-1.0024 0.0560 TNFRSF10A TRALIR, CD261 TNFRSF 1.0336 0.4842-1.256 0.7428 TNFRSF10C TRALIRA, CD264 TNFRSF 0.8682 0.9277-0.0544 0.0069 TNFRSF11A RANK, CD265 TNFRSF 0.1036 0.4842-1.256 <td>FASLG</td> <td>TNFSF6, CD95-L</td> <td>TNFSF</td> <td>0.9083</td> <td>0.8204-1.0056</td> <td>0.0641</td>	FASLG	TNFSF6, CD95-L	TNFSF	0.9083	0.8204-1.0056	0.0641
ICOS CD278, CVID1 CD28 0.8970 0.8022.0942 0.0381 ICOSLG B742, CD275 B7 0.8427 0.7104.0996 0.0495 ITA TNFSF1 TNFSF 0.8711 0.7949.0679 0.0391 ITB TNFSF3 TNFSF 1.3077 1.0591-1.6147 0.026 NGFR TNFRSF16, CD271 TNFRSF 1.0011 0.9123-1.0966 0.9808 PDCD11 PD-1, CD279 CD28 0.9625 0.6693-1.0658 0.4630 PDC014 PD-1, CD279 CD28 0.9259 0.7844-1.0873 0.3477 MIGD2 CD28H CD28 0.9259 0.7844-1.0873 0.3477 MIGD2 CD28H CD28 0.9259 0.7844-1.0873 0.3477 MIGD3 TNFRSF 10. TNFRSF 0.9090 0.8279-1.043 0.0269 TMFSF108 TRALIR1, CD261 TNFRSF 0.9098 0.8257-1.074 0.0485 TMFSF100 TRALIR3, CD263 TNFRSF 0.8082 0.7727.0.6634 0.0697	HHLA2	B7-H5	B7	1.0016	0.9602-1.0448	0.9414
ICOSLG B7-H2, CD275 B7 0.8427 0.7104-0996 0.0495 LTA TNFSF1 TNSFF 0.8918 0.8020-09939 0.0385 LTB TNFSF3 TNFSF 0.8771 0.7949-0.679 0.0091 LTB TNFRSF3 TNFRSF 1.3077 1.0591-1.6147 0.0126 NGFR TNFRSF16, CD271 TNFRSF 1.0011 0.9123-1.0986 0.9808 PDCD1 PD-1, CD279 CD28 0.9625 0.68693-1.0658 0.4630 PDCD1 TNFRSF19L TNFRSF 0.9259 0.7884-1.0873 0.3477 TMGD2 CD28H CD28 0.9250 0.8279-1.0423 0.2066 TNFSF10B TRALLR1, CD21 TNFRSF 1.0582 0.2025-1.4024 0.0561 TNFRSF10B TRALLR2, CD263 TNFRSF 1.0582 0.3025-1.2024 0.04647 TNFRSF11B CPG TNFRSF 1.0582 0.3992-1.2020 0.0647 TNFRSF11B RALLR2, CD265 TNFRSF 1.0586 0.9191-1.135	ICOS	CD278, CVID1	CD28	0.8970	0.8092-0.9942	0.0384
LTA TNFSF1 TNFSF 0.8002-0.9939 0.0385 LTB TNFSF3 TNFSF 0.8771 0.7949-0.9679 0.0091 LTBR TNFRSF1 1.0011 0.9121-0.16147 0.0126 NGFR TNFRSF1 1.0011 0.9121-0.1086 0.9808 POCD1 PD-1, CD279 CD28 0.9623 0.8693-1.0658 0.4630 POCD102 PD-12, B70C, CD273 B7 0.9691 0.8733-1.0754 0.5544 RELT TNFRSF104 TNFRSF 0.9290 0.8279-1.0423 0.2096 TNF TNFRSF105 TALRI, CD261 TNFRSF 0.9098 0.8227-1.0024 0.0687 TNFRSF106 TRALIR2, CD262 TNFRSF 1.0336 0.8482-1.2596 0.7428 TNFRSF11A RALR2, CD264 TNFRSF 1.0799 0.9334-1.2485 0.3015 TNFRSF11A RALR4, CD266 TNFRSF 1.1040 0.9788-1.2477 0.1131 TNFRSF13A FNLR4, CD266 TNFRSF 0.8082 0.9797-0.9434 0.0009 <	ICOSLG	B7-H2, CD275	B7	0.8427	0.7104-0.9996	0.0495
LTB TMFSF3 TMFSF 0.871 0.7949-0.9679 0.0091 LTBR TMFRSF16, CD271 TMFRSF 1.3077 1.0591-1.6147 0.0126 NGFR TMFRSF16, CD271 TMFRSF 1.0011 0.9123-1.0986 0.9808 POCD1 PD-1, CD279 CD28 0.9625 0.86931-0.0558 0.4630 POCD1 PD-1, CD279 CD28 0.9259 0.7884-1.0873 0.3447 RELT TMFRSF101 TMFRSF 0.9259 0.7884-1.0873 0.3447 TMG02 CD28H CD28 0.9290 0.8279-1.024 0.0560 TMFSF10A TRALR2, CD261 TMFRSF 1.0382 0.9025-1.2068 0.4823 TMFRSF10B TAALR3, CD263 TMFRSF 1.0382 0.9234-1.2495 0.3157 TMFRSF11B OFG TMFRSF 1.0388 0.9139-1.1135 0.8619 TMFRSF13B TACL, TMFRSF14A, CD264 TMFRSF 1.0400 0.9762-1.2477 0.1131 TMFRSF13B TACL, TMFRSF14A, CD264 TMFRSF 0.82783	LTA	TNFSF1	TNFSF	0.8918	0.8002-0.9939	0.0385
LTBR TNFRSF 1, 3077 1.0591-1.6147 0.0125 NGFR TNFRSF 16, CD271 TNFRSF 1, 1.0011 0.912.1.0986 0.9808 POCD1 PD-L2, B7DC, CD273 B7 0.6691 0.8733.1.0754 0.5544 RELT TNFRSF 19L TNFRSF 0.2299 0.7884.1.0873 0.3477 MIGD2 CD28H CD28 0.9290 0.8279-1.0024 0.0560 TNFSF 10A TRALLR, CD261 TNFRSF 0.3052 0.9025-1.2408 0.4868 NFRSF 10A TRALLR, CD262 TNFRSF 1.0356 0.4862.1.2596 0.7428 NFRSF 10C TRALLRA, CD264 TNFRSF 1.0799 0.9334.1.2495 0.3015 NFRSF 11A RALKR, CD265 TNFRSF 1.0140 0.9727-0.9634 0.0089 NFRSF 11A RALKR, CD264 TNFRSF 1.0088 0.9139.1.1135 0.8619 NFRSF 11A RALKR, CD265 TNFRSF 1.0088 0.9977-0.9682 0.0090 NFRSF 13A CL, TNFRSF 1446, CD267 TNFRSF 0.06862 0.7877 <td< td=""><td>LTB</td><td>TNFSF3</td><td>TNFSF</td><td>0.8771</td><td>0.7949-0.9679</td><td>0.0091</td></td<>	LTB	TNFSF3	TNFSF	0.8771	0.7949-0.9679	0.0091
NGFR TNFRSF 16, CD271 TNFRSF 1.011 0.9123-10986 0.98085 PDCD1 PD-1, CD279 CD28 0.9625 0.6893-10658 0.4630 PDCD1 PD-1, CD279 CD28 0.9259 0.7844-10873 0.3477 TMIGD2 CD28H CD28 0.9290 0.8279-10423 0.2066 TMF TNFSF12, TNFA TNFSF 0.9088 0.8257-1.0024 0.0560 TNFRSF106 TRALLR, CD261 TNFRSF 1.0352 0.9025-1.2406 0.4858 TNFRSF106 TRALLR, CD263 TNFRSF 1.0356 0.7428 0.0087 TNFRSF100 TRALLR, CD264 TNFRSF 1.0368 0.9139-11135 0.8619 TNFRSF118 OPG TNFRSF 1.0040 0.9768-1.2477 0.1131 NFRSF132 BAFFR, CD266 TNFRSF 0.8082 0.7907-0.9634 0.0099 NFRSF134 LGHTR, HVEAKR, CD267 TNFRSF 0.8082 0.797-0.9684 0.0096 NFRSF135 DAFFS 1.0088 0.9139-11135 0.819	LTBR	TNFRSF3	TNFRSF	1.3077	1.0591-1.6147	0.0126
PDCD1 PD-1, E0279 CD28 0.9625 0.8693-1.0658 0.4630 PDCD1L2 PD-12, B70C, CD273 B7 0.9691 0.8733-10754 0.5544 RELT TNRFSF19L TNFRSF 0.9290 0.8277-10024 0.0307 TMFC CD28H CD28 0.9290 0.8277-10024 0.0450 TNFF TNFSF2, TNFA TNFSF 0.9098 0.8257-10024 0.04858 TNFRSF10B TRALLR3, CD262 TNFRSF 1.0336 0.8482-12586 0.7428 TNFRSF10C TRALLR4, CD264 TNFRSF 1.0799 0.9334-12495 0.3015 TNFRSF11A RALKR, CD265 TNFRSF 1.0088 0.9193-1.1135 0.8619 TNFRSF11A FNI4, TWEAKR, CD266 TNFRSF 1.0040 0.9766-1.2477 0.131 TNFRSF13C BAFFR, CD268 TNFRSF 0.8682 0.7977-0.9682 0.0009 TNFRSF131 BAFFR, CD269 TNFRSF 0.8682 0.7977-0.9682 0.0073 TNFRSF131 BAFFR, CD268 TNFRSF 0.8	NGFR	TNFRSF16, CD271	TNFRSF	1.0011	0.9123-1.0986	0.9808
PDCD1LG2 PD-L2, 87DC, CD273 B7 0.9691 0.8733-10754 0.5544 RELT TMFRSF19L TNFRSF 0.9259 0.7884-1.0873 0.3477 TMIGD2 CD28H CD28 0.9290 0.8279-1.0423 0.0560 TNFRSF10A TRAILR1, CD261 TNFRSF 0.908 0.8225-1.0024 0.0560 TNFRSF10A TRAILR2, CD262 TNFRSF 1.0336 0.84426-1.2596 0.7428 TNFRSF10D TRAILR3, CD263 TNFRSF 0.8628 0.7727-0.9634 0.0087 TNFRSF10D TRAILR4, CD264 TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11B OPG TNFRSF 1.0308 0.9139-1.135 0.8619 TNFRSF11A RANK, CD265 TNFRSF 1.0400 0.9768-1.2477 0.1131 TNFRSF13B TACI, TNFRSF14B, CD267 TNFRSF 0.8008 0.8370-0.9438 0.0009 TNFRSF13F LGHTR, MYEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF14 LGHTR, MYEM, CD270 <td< td=""><td>PDCD1</td><td>PD-1, CD279</td><td>CD28</td><td>0.9625</td><td>0.8693-1.0658</td><td>0.4630</td></td<>	PDCD1	PD-1, CD279	CD28	0.9625	0.8693-1.0658	0.4630
RELT TMFRSF 10. TMFRSF 0.9259 0.7884-1.0873 0.3477 TMIGD2 CD28H CD28H 0.9998 0.8279-1.024 0.0500 TNF TMFSF, TMA TMFSF 0.9998 0.8279-1.024 0.0560 TNFRSF 1.0582 0.9025-1.2408 0.4858 0.7428 0.7428 TMFRSF10C TRAILR3, CD263 TMFRSF 1.0336 0.4842-1.2566 0.7428 TMFRSF10C TRAILR4, CD264 TMFRSF 1.0799 0.9334-1.2495 0.3015 TMFRSF11A RAW, CD265 TMFRSF 1.088 0.9139-1.1135 0.8619 TMFRSF13B OPG TMFRSF 1.088 0.9139-1.1135 0.8619 TMFRSF13C BAFFR, CD266 TMFRSF 1.088 0.9139-1.1135 0.8619 TMFRSF13L IMFRSF13A, CD267 TMFRSF 0.8682 0.7987-0.9488 0.0009 TMFRSF13B TAC, TMFRSF14B, CD268 TMFRSF 0.8682 0.7970-0.9682 0.0009 TMFRSF13B GFRA, ATR, CD357 TMFRSF 0.98	PDCD1LG2	PD-L2, B7DC, CD273	B7	0.9691	0.8733-1.0754	0.5544
TMIGD2 CD28H CD28 0.9290 0.8279-1.0423 0.2096 TNF TNFSF; TAFA TNFSF 0.9098 0.8257-1.0024 0.0560 TNFSF10A TRAILR1, CD261 TNFRSF 1.0582 0.9025-1.2408 0.44858 TNFRSF10B TRAILR3, CD263 TNFRSF 0.8628 0.7727-0.9634 0.0087 TNFRSF10D TRAILR3, CD265 TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11B OPG TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11B OPG TNFRSF 1.1316 0.9926-1.2902 0.0647 TNFRSF11B OPG TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF13C BAFFR, CD268 TNFRSF 0.8253 0.7712-0.9632 0.0073 TNFRSF13 BAFR, CD269 TNFRSF 0.8253 0.7712-0.9682 0.0009 TNFRSF17 BCMA, TNFRSF13A, CD269 TNFRSF 0.8253 0.0360-1.0860 0.8607 TNFRSF18 GTR, AITR, CD357 TNFRSF 0.85	RELT	TNFRSF19L	TNFRSF	0.9259	0.7884-1.0873	0.3477
TNF TNFSF2, TNFA TNFSF 0.9098 0.8257-1.0024 0.0560 TNFRSF10A TAILLR1, CD261 TNFRSF 1.0582 0.9025-1.2408 0.4858 TNFRSF10B TAILLR3, CD262 TNFRSF 0.336 0.8482-1.2596 0.7428 TNFRSF10C TAILR3, CD263 TNFRSF 1.0799 0.9334-1.2495 0.0017 TNFRSF11A RANK, CD265 TNFRSF 1.0308 0.9133-1.12495 0.0017 TNFRSF11A RANK, CD266 TNFRSF 1.0400 0.9768-1.2477 0.1131 TNFRSF13A FN14, TWEAKR, CD266 TNFRSF 0.8682 0.7977-0.9682 0.0009 TNFRSF13A BAFFR, CD268 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF134 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.712-0.9573 0.0073 TNFRSF18 GTR, ATR, CD357 TNFRSF 0.8253 0.712-0.9577 0.0073 TNFRSF18 GTR, ATR, CD357 TNFRSF 0.8604 0.7360-1.0142 0.0739 TNFRSF18 GTR3, ATR, CD357	TMIGD2	CD28H	CD28	0.9290	0.8279-1.0423	0.2096
TNFRSF10A TRAILR1, CD261 TNFRSF 1.0582 0.9025-1.2408 0.4858 TNFRSF10B TRAILR2, CD262 TNFRSF 0.36628 0.7727-0.9634 0.0087 TNFRSF10D TRAILR3, CD263 TNFRSF 1.0799 0.9334-1.2495 0.3015 TNFRSF11A RANK, CD265 TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11B OPG TNFRSF 1.1040 0.9786-1.2477 0.1131 TNFRSF132 FN14, TWEAKR, CD266 TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF132 BAFFR, CD268 TNFRSF 0.8682 0.7977-0.9682 0.0090 TNFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8678 0.7177-0.9682 0.0090 TNFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8233 0.7112-0.9577 0.0114 TNFRSF18 GIR, AITR, CD357 TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF14 TNFR1, CD120A TNFRSF 0.8640 0.3366-1.0142 0.0739 TNFRSF18 GIRA, AITR, CD357 TNFRSF 0.8640 0.3366-1.0142 0.0739 <tr< td=""><td>TNF</td><td>TNFSF2, TNFA</td><td>TNFSF</td><td>0.9098</td><td>0.8257-1.0024</td><td>0.0560</td></tr<>	TNF	TNFSF2, TNFA	TNFSF	0.9098	0.8257-1.0024	0.0560
INFRSF108 IRAIR2, CD262 INFRSF 1.0336 0.8482-1,2596 0.7428 INFRSF10C TRAIR3, CD263 TNFRSF 0.8628 0.772-0.9634 0.0087 INFRSF10D TRAILR4, CD264 TNFRSF 1.0799 0.9334-1.2495 0.3015 TNFRSF11A RANK, CD265 TNFRSF 1.08628 0.7132-1.2902 0.0647 TNFRSF11A RANK, CD265 TNFRSF 1.040 0.9768-1.2477 0.1131 TNFRSF13A FN14, TWEAKR, CD266 TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF13K TACI, TNFRSF148, CD267 TNFRSF 0.8788 0.7777-0.9682 0.0090 TNFRSF14 LIGHTR, MER, CD269 TNFRSF 0.8253 0.7112-0.9577 0.0173 TNFRSF19 TNR, CD120 TNFRSF 0.8256 0.7735-0.9553 0.0050 TNFRSF19 TNFRSF 0.8256 0.7735-0.9553 0.00179 TNFRSF18 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF18 TNFRSF 1.041 0.9425-1.2935	TNFRSF10A	TRAILR1, CD261	TNFRSF	1.0582	0.9025-1.2408	0.4858
TNFRSF10C TRAILR3, CD263 TNFRSF 0.8628 0.7727-0.9634 0.0087 TNFRSF10D TRAILR4, CD264 TNFRSF 1.0799 0.9334-1.2495 0.3015 TNFRSF11B OPG TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11B OPG TNFRSF 1.0404 0.9768-1.2477 0.1131 TNFRSF13B TACI, TNFRSF 148, CD266 TNFRSF 0.8682 0.7997-0.9682 0.0090 TNFRSF13C BAFFR, CD268 TNFRSF 0.8682 0.7977-0.9682 0.0090 TNFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF17 BCMA, TNFRSF13A, CD269 TNFRSF 0.8253 0.7735-0.9553 0.0050 TNFRSF19 TNFR, CD357 TNFRSF 0.8256 0.7735-0.9553 0.0050 TNFRSF18 TNFR, CD120A TNFRSF 0.3840 0.7360-1.0142 0.0733 TNFRSF18 TNFR, CD120A TNFRSF 0.3840 0.7360-1.0142 0.0733 TNFRSF19 TNFRSF 0.3840 0.7360-1.0142 0.0733 0.9842-1.7500 0.0179	TNFRSF10B	TRAILR2, CD262	TNFRSF	1.0336	0.8482-1.2596	0.7428
INFRSF10D INFRSF 1.0799 0.9334-1.2495 0.3015 INFRSF11A RANK, CD265 TNFRSF 1.1316 0.9925-1.2902 0.0647 TNFRSF11A RANK, CD265 TNFRSF 1.1040 0.9768-1.2477 0.1131 TNFRSF11B OPG TNFRSF 1.1040 0.9768-1.2477 0.1131 TNFRSF13C BAFFR, CD268 TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF13C BAFFR, CD268 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF18 GTR, ATR, CD270 TNFRSF 0.8253 0.712-0.9577 0.0114 TNFRSF18 GTR, ATR, CD257 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF18 GTR, ATR, CD204 TNFRSF 0.3583 0.0735-0.9553 0.0050 TNFRSF18 TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF18 TNFRSF 1.0411 0.9425-1.2950 0.2201 TNFRSF2 0.8564 0.736-1.0142 0.0735 TNFRSF4 0.510 0.8323-1.0867 0.4607 TNFRSF5 0.9513 0.8376-1.0241 0.1349 TNFRSF2 0.9513 0.8376-1.0241 0.1349 TNFRSF5 0.9513 0.8	TNFRSF10C	TRAILR3, CD263	TNFRSF	0.8628	0.7727-0.9634	0.0087
INFRSF11A MANK, CD25 INFRSF 1.316 0.9925-1.2902 0.064/ TNFRSF11B OPG TNFRSF 1.0088 0.9139-1.1135 0.8619 TNFRSF11B TACI, TNFRSF14B, CD266 TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF13C BAFFR, CD268 TNFRSF 0.8682 0.7977-0.9682 0.0009 TNFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.9023 0.8370-0.9727 0.0073 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF1A TNR1, CD120A TNFRSF 0.3584 0.0173 TNFRSF 0.8464 0.7360-1.0142 0.0735 TNFRSF1A TNR1, CD120A TNFRSF 0.8464 0.7360-1.0142 0.0735 TNFRSF1A TNR1, CD120A TNFRSF 0.8464 0.7360-1.0142 0.0735 TNFRSF1A TNR1, CD120A TNFRSF 0.8640 0.7360-1.0241 0.1349 <	TNFRSF10D	TRAILR4, CD264	TNFRSF	1.0799	0.9334-1.2495	0.3015
INFRST1B OPG INFRST 1.0088 0.9139-1.1135 0.8619 TNFRSF12A FN14, TWEAKR, CD266 TNFRSF 1.1040 0.9768-1.2477 0.1131 TNFRSF13B TACI, TNFRSF14B, CD267 TNFRSF 0.8682 0.7987-0.9438 0.0009 TNFRSF13C BAFFR, CD268 TNFRSF 0.8788 0.7977-0.9682 0.0009 TNFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNFRSF18 GITR, AITR, CD269 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF19 TROY, TAJ TNFRSF 0.8560 0.735-0.9553 0.0050 TNFRSF18 TNFR1, CD120A TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF18 DR3, TNFRSF12 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF2 DR6, CD358 TNFRSF 1.1041 0.9425-1.2935 0.2021 TNFRSF8 DR3, TNFRSF12 <td>INFRSF11A</td> <td>RANK, CD265</td> <td>INFRSF</td> <td>1.1316</td> <td>0.9925-1.2902</td> <td>0.064/</td>	INFRSF11A	RANK, CD265	INFRSF	1.1316	0.9925-1.2902	0.064/
INFRSF12A FNI4, IWEAR, CD266 INFRSF 1,1040 0.9768-1.2477 0.1131 INFRSF13B TAC, IYRESF14B, CD267 TNFRSF 0.8682 0.7987-0.9682 0.0090 INFRSF13C BAFFR, CD268 TNFRSF 0.8253 0.7112-0.9577 0.0113 INFRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0073 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.9023 0.8370-0.9727 0.0073 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF18 TNRY, TAJ TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF18 TNRY, CD120A TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF18 TNFR2, CD120B TNFRSF 0.8640 0.7360-1.0142 0.7397 TNFRSF14 DR6, CD358 TNFRSF 0.9622 0.8376-1.0241 0.1349 TNFRSF6 DR3, TNFRSF12 TNFRSF 0.9513 0.8323-1.0867 0.4007 TNFRSF8 CD30 TNFRSF 0.9513 0.8343-1.0847 0.4560 T	INFRSF11B	OPG	INFRSF	1.0088	0.9139-1.1135	0.8619
INFRSF13B IAU, INFRSF14B, CD267 INFRSF 0.8682 0.7987-0.9482 0.0009 TNFRSF13C BAFFR, CD268 TNFRSF 0.87788 0.7712-0.9577 0.0114 TNFRSF17 BCMA, TNFRSF13A, CD269 TNFRSF 0.9023 0.8370-0.9727 0.0073 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF18 TNFR, CD120A TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF1A TNFR, CD120A TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF1A TNFR, CD120A TNFRSF 0.3660 0.7360-1.0142 0.0739 TNFRSF1A TNFR, CD120A TNFRSF 0.3640 0.7360-1.0142 0.0739 TNFRSF1A DR6, CD358 TNFRSF 0.9262 0.8376-1.0241 0.1349 TNFRSF68 DC83 TNFRSF 0.9513 0.8343-1.0867 0.4607 TNFRSF9 4.188, CD137, ILA TNFRSF 0.9513 0.8343-1.0867 0.4501 TNFSF13 TANL, CD254	INFRSF12A	FN14, TWEAKK, CD266	INFRSF	1.1040	0.9/68-1.24//	0.1131
INFRSF13C BAFFR, CU28S INFRSF 0.8788 0.797/-0.9682 0.0090 TNRRSF14 LIGHTR, HVEM, CD270 TNFRSF 0.8253 0.7112-0.9577 0.0114 TNRRSF18 GIR, AITR, CD357 TNFRSF 0.9023 0.8370-0.9727 0.0073 TNRSF18 GIR, AITR, CD357 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNRSF14 TNFRSF 0.8596 0.7735-0.9553 0.0050 TNRSF14 TNFR1, CD120A TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF18 TNFR2, CD120B TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF12 DR6, CD358 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF4 DX40, CD134 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF8 CD30 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF1 TNFRSF 0.9837 0.9007-1.0744 0.7156 TNFRSF1 TNFRSF 0.9837 0.9007-1.0744 0.7156 <td>INFRSF13B</td> <td>TACI, TNFRSF14B, CD267</td> <td>INFRSF</td> <td>0.8682</td> <td>0.7987-0.9438</td> <td>0.0009</td>	INFRSF13B	TACI, TNFRSF14B, CD267	INFRSF	0.8682	0.7987-0.9438	0.0009
INFRSF14 LIGHTR, HVEN, CD2/0 INFRSF 0.8253 0.712-0.577 0.0114 NTRRSF17 BCMA, TNFRSF13A, CD269 TNFRSF 0.9023 0.8370-0.9727 0.0073 TNFRSF18 GITR, AITR, CD357 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF19 TROY, TAJ TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF18 TNFR2, CD1208 TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF18 TNFR2, CD1208 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF18 DR6, CD358 TNFRSF 0.9662 0.8323-1.0867 0.4607 TNFRSF25 DR3, TNFRSF12 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF8 CD30 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF10 TRAL, CD253 TNFRSF 0.9813 0.831-1.037 0.0022 TNFRSF12 TRAL TNFRSF 0.9817 0.9007-1.0744 0.7560 TNFRSF10 TRAL, CD253 TNFSF	INFRSF13C	BAFFR, CD268	INFRSF	0.8/88	0.7977-0.9682	0.0090
INFRSF17 BCMA, INFRSF13A, CD269 INFRSF 0.9023 0.837/0-0.9727 0.0073 TNFRSF18 GIR, AITR, CD357 TNFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF18 TROY, TAJ TNFRSF 0.8596 0.7735-0.9553 0.0050 TNFRSF18 TNFR1, CD120A TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF18 TNFR2, CD120B TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF12 DR6, CD358 TNFRSF 0.9262 0.8376-1.0241 0.1349 TNFRSF25 DR3, TNFRSF12 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF6B DCR3 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF8 CD30 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF10 TRAIL, CD253 TNFRSF 0.9685 0.9907-1.0744 0.7156 TNFSF13 APRL, CD254 TNFSF 0.9837 0.9007-1.0744 0.7156 TNFSF13 APRL, CD256 TNFSF	INFRSF14	LIGHTR, HVEM, CD2/0	INFRSF	0.8253	0.7112-0.9577	0.0114
INFRSF18 GHR, AIR, CDS37 INFRSF 0.9919 0.9060-1.0860 0.8607 TNFRSF19 TNOY, TAJ TNFRSF 0.8596 0.735-0.9553 0.0007 TNFRSF18 TNFR3, CD1208 TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF18 TNFR2, CD1208 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF25 DR3, TNFRSF12 TNFRSF 0.9262 0.8376-1.0241 0.1349 TNFRSF8 0.9262 0.8376-1.0241 0.4607 0.4607 TNFRSF8 DC83 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF8 DC93 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF9 4-18B, CD137, ILA TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFSF10 TRAIL, CD253 TNFRSF 0.9837 0.9007-1.0744 0.7156 TNFSF13 APRIL, CD254 TNFSF 0.9847 0.9262 0.0038 TNFSF13 APRIL, CD256 TNFSF 0.7643 0.631-0.9226 <td></td> <td>BUMA, INFRSFI3A, CD269</td> <td>INFRSF</td> <td>0.9023</td> <td>0.8370-0.9727</td> <td>0.0073</td>		BUMA, INFRSFI3A, CD269	INFRSF	0.9023	0.8370-0.9727	0.0073
INFRSF 19 INOT, IA INFRSF 0.8390 0.7735-0.9533 0.0003 TNFRSF IA TNFR1, CD 120A TNFRSF 1.3583 1.0542-1.7500 0.0179 TNFRSF IB TNFR2, CD 120B TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF IB DR6, CD358 TNFRSF 0.8640 0.7360-1.0142 0.0739 TNFRSF25 DR3, TNFRSF12 TNFRSF 0.9262 0.8376-1.0241 0.1349 TNFRSF6B DCR3 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF6B DCR3 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF6 D30 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF11 RANKL, CD253 TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF12 TWEAK TNFSF 0.9741 0.6331-0.9226 0.0051 TNFSF13 APRIL, CD254 TNFSF 0.7978 0.6847-0.9296 0.0038 TNFSF13B BAFF, CD257 TNFSF 0.9989 <t< td=""><td></td><td></td><td></td><td>0.9919</td><td>0.9060-1.0860</td><td>0.8607</td></t<>				0.9919	0.9060-1.0860	0.8607
INFRSTAINFRSTAINFRSF1.35831.0542-1.75000.0179TNFRSF1BTNFR2, CD120BTNFRSF0.86400.7360-1.01420.0739TNFRSF21DR6, CD358TNFRSF1.10410.9425-1.29350.2201TNFRSF25DR3, TNFRSF12TNFRSF0.92620.8376-1.02410.1349TNFRSF6BDCR3TNFRSF0.95100.8323-1.08670.4607TNFRSF6BDCR3TNFRSF0.95130.8343-1.08470.0022TNFRSF94-1BB, CD137, ILATNFRSF0.99370.9007-1.07440.7166TNFSF10TRAL, CD253TNFSF0.97410.8621-1.10070.6740TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.79780.6847-0.92960.0038TNFSF14LIGHT, HVEML, CD258TNFSF0.99890.8846-1.10560.8448TNFSF15TL1ATNFSF0.99120.8391-1.01130.8448TNFSF18GITRLTNFSF0.92120.8391-1.01130.0848TNFSF8CD30, CD133TNFSF0.88640.7979-0.98480.0247TNFSF94.188-L, CD137LTNFSF0.88640.7979-0.98480.0247TNFSF94.188-L, CD137LTNFSF1.08880.9787-1.21120.1177VTCN1B7-H4B70.97320.9192-1.03040.3513				0.8590	0.7735-0.9553	0.0050
INFRSF10INFRSF0.80400.7300-101420.0230TNFRSF21DR6, CD358TNFRSF1.10410.9425-129350.2201TNFRSF25DR3, TNFRSF12TNFRSF0.92620.8376-1.02410.1349TNFRSF4OX40, CD134TNFRSF0.95100.8323-1.08670.4607TNFRSF6BDCR3TNFRSF1.13991.0481-1.23970.0022TNFRSF8CD30TNFRSF0.95130.8343-1.08470.4560TNFRSF94-1BB, CD137, ILATNFRSF0.98370.9007-1.07440.7156TNFSF10TRAIL, CD253TNFSF0.97410.8621-1.10070.6740TNFSF11RANKL, CD254TNFSF1.06850.9942-1.14840.0717TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.98890.8846-1.10560.8488TNFSF14LIGHT, HVEML, CD258TNFSF0.98890.8846-1.10560.8488TNFSF15TL1ATNFSF0.92120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF8CD30L, CD134L, CD252TNFSF1.03230.9090-1.17230.6246TNFSF94-18B-L, CD137LTNFSF0.88640.9797-0.98480.247TNFSF94-18B-L, CD137LTNFSF1.08880.9787-1.21120.1177TNFSF94-18B-L, CD137LTNFSF0.97320.9192-1.03040.3513				1.3383	1.0542-1.7500	0.01/9
INFRSF21 DR0, CD536 INFRSF 1.1041 0.942512933 0.2201 TNFRSF25 DR3, TNFRSF12 TNFRSF 0.9262 0.8376-1.0241 0.1349 TNFRSF4 OX40, CD134 TNFRSF 0.9510 0.8323-1.0867 0.4607 TNFRSF6B DCR3 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF9 4-18B, CD137, ILA TNFRSF 0.99837 0.9007-1.0744 0.7156 TNFSF10 TRAIL, CD253 TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF12 TWEAK TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF12 TWEAK TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF13 APRIL, CD254 TNFSF 0.7643 0.6331-0.9226 0.0051 TNFSF13 APRIL, CD256 TNFSF 0.9889 0.8846-1.1056 0.8448 TNFSF14 LIGHT, HVEML, CD258 TNFSF 0.9912 0.8391-1.0113 0.0848 TNFSF18 GITRL TNFSF 0.99212				0.0040	0.7500-1.0142	0.0739
INFNSF23DNS, INFNSF12INFNSF0.52020.8370-1.02410.1349TNFRSF4OX40, CD134TNFRSF0.95100.8323-1.08670.4607TNFRSF6BDCR3TNFRSF1.13991.0481-1.23970.0222TNFRSF94-1BB, CD137, ILATNFRSF0.95130.8343-1.08470.4560TNFSF10TRAIL, CD253TNFSF0.98370.9007-1.07440.7156TNFSF11RANKL, CD254TNFSF0.97410.8621-1.10070.6740TNFSF13APRIL, CD256TNFSF0.76430.6331-0.92260.0051TNFSF13BAFF, CD257TNFSF0.79780.6847-0.92960.0038TNFSF14LIGHT, HVEML, CD258TNFSF0.99420.8391-1.01560.8448TNFSF15TL1ATNFSF0.92120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF18CD30L, CD134L, CD252TNFSF1.03230.9090-1.17230.6246TNFSF8CD30L, CD134L, CD252TNFSF1.08860.7979-0.98480.0247TNFSF94-18B-L, CD137LTNFSF1.08860.9787-1.21120.1177VTCN1B7-H4B70.97320.9192-1.03040.3513				0.0262	0.9425-1.2955	0.2201
INITISITY0.53100.5323-1.08070.400TNFRSF6BDCR3TNFRSF1.13991.0481-1.23970.0022TNFRSF8CD30TNFRSF0.95130.8343-1.08470.4560TNFRSF94-1BB, CD137, ILATNFRSF0.98370.9007-1.07440.7156TNFSF10TRAIL, CD253TNFSF0.97410.8621-1.10070.6740TNFSF11RANKL, CD254TNFSF1.06850.9942-1.14840.0717TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.79780.6847-0.92960.0038TNFSF14LIGHT, HVEML, CD258TNFSF0.98890.8846-1.10560.8448TNFSF15TL1ATNFSF0.92120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF8CD30L, CD134L, CD252TNFSF0.88640.7979-0.98480.0247TNFSF94-18B-L, CD137LTNFSF0.88640.9978-1.21120.1177VTCN1B7-H4B70.97320.9192-1.03040.3513		OYAO CD13A		0.9202	0.8370-1.0241	0.1549
TNFRSF8 CD30 TNFRSF 0.9513 0.8343-1.0847 0.4560 TNFRSF9 4-1BB, CD137, ILA TNFRSF 0.9837 0.9007-1.0744 0.7156 TNFSF10 TRAIL, CD253 TNFSF 0.9837 0.9002-1.1074 0.6740 TNFSF11 RANKL, CD254 TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF12 TWEAK TNFSF 0.7643 0.6331-0.9226 0.0051 TNFSF13 APRIL, CD256 TNFSF 0.7978 0.6847-0.9296 0.0038 TNFSF13B BAFF, CD257 TNFSF 0.9889 0.8846-1.1056 0.8448 TNFSF15 TL1A TNFSF 0.9212 0.8391-1.0113 0.0848 TNFSF18 GITRL TNFSF 0.8992 0.7838-1.0316 0.1296 TNFSF8 CD30L, CD134L, CD252 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF8 CD30L, CD137L TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-188-L, CD137L TNFSF 0.8864 0.9978-1.2112 0.1177 VTCN1 B7-H4 B7 0				1 1300	1 0/91-1 2307	0.4007
INITISTO0.59130.69430.6049TNFRSF4-1BB, CD137, ILATNFRSF0.98370.9007-1.07440.7156TNFSF10TRAIL, CD253TNFSF0.98370.9007-1.07440.6740TNFSF11RANKL, CD254TNFSF1.06850.9942-1.14840.0717TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.79780.6847-0.92960.0038TNFSF13BBAFF, CD257TNFSF0.98890.8846-1.10560.8448TNFSF14LIGHT, HVEML, CD258TNFSF0.90120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF18GITRLTNFSF0.88640.7979-0.98480.0247TNFSF8CD30L, CD134L, CD252TNFSF1.08880.9787-1.21120.1177VTCN1B7-H4B70.97320.9192-1.03040.3513	TNERSE8		TNERSE	0 9513	0.8343-1.0847	0.0022
TNFSF10 TRAIL, CD253 TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF11 RANKL, CD254 TNFSF 0.9741 0.8621-1.1007 0.6740 TNFSF12 TWEAK TNFSF 0.7643 0.6331-0.9226 0.0051 TNFSF13 APRIL, CD256 TNFSF 0.7978 0.6847-0.9296 0.0038 TNFSF13B BAFF, CD257 TNFSF 0.9889 0.8846-1.1056 0.8448 TNFSF14 LIGHT, HVEML, CD258 TNFSF 0.9212 0.8391-1.0113 0.0848 TNFSF18 GITRL TNFSF 0.8992 0.7838-1.0316 0.1296 TNFSF18 GITRL TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF8 CD30L, CD134L, CD252 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-188-L, CD137L TNFSF 0.8864 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNERSEQ	Δ-18B CD137 II Δ	TNERSE	0.9915	0.9007-1.0744	0.4500
INFSF10INFSF0.57410.5021 11.1070.6740TNFSF11RANKL, CD254TNFSF1.06850.9942-1.14840.0717TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.79780.6847-0.92960.0038TNFSF13BBAFF, CD257TNFSF0.98890.8846-1.10560.8448TNFSF14LIGHT, HVEML, CD258TNFSF1.00940.9061-1.12460.8648TNFSF15TL1ATNFSF0.92120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF8CD30L, CD134L, CD252TNFSF1.03230.9090-1.17230.6247TNFSF94-18B-L, CD137LTNFSF0.88640.7979-0.98480.0247VTCN1B7-H4B70.97320.9192-1.03040.3513	TNESE10		TNIESE	0.9037	0.8621-1 1007	0.7150
INISTINISTI.00030.79421.14040.7017TNFSF12TWEAKTNFSF0.76430.6331-0.92260.0051TNFSF13APRIL, CD256TNFSF0.79780.6847-0.92960.0038TNFSF13BBAFF, CD257TNFSF0.98890.8846-1.10560.8448TNFSF14LIGHT, HVEML, CD258TNFSF1.00940.9061-1.12460.8648TNFSF15TL1ATNFSF0.92120.8391-1.01130.0848TNFSF18GITRLTNFSF0.89920.7838-1.03160.1296TNFSF4OX-40L, CD134L, CD252TNFSF1.03230.9090-1.17230.6246TNFSF8CD30L, CD153TNFSF0.88640.7979-0.98480.0247TNFSF94-18B-L, CD137LTNFSF1.08880.9787-1.21120.1177VTCN1B7-H4B70.97320.9192-1.03040.3513	TNESE11	RANKI CD254	TNIESE	1 0685	0.9942-1.1484	0.0740
TNFSF12 APRIL, CD256 TNFSF 0.7978 0.6847-0.9296 0.0038 TNFSF13 APRIL, CD256 TNFSF 0.7978 0.6847-0.9296 0.0038 TNFSF13 BAFF, CD257 TNFSF 0.9889 0.8846-1.1056 0.8448 TNFSF14 LIGHT, HVEML, CD258 TNFSF 1.0094 0.9061-1.1246 0.8648 TNFSF15 TL1A TNFSF 0.9212 0.8391-1.0113 0.0848 TNFSF18 GITRL TNFSF 0.8992 0.7838-1.0316 0.1296 TNFSF4 OX-40L, CD134L, CD252 TNFSF 1.0323 0.9090-1.1723 0.6246 TNFSF8 CD30L, CD153 TNFSF 0.8864 0.7979-0.9848 0.6247 TNFSF9 4-18B-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNESE12	TW/FAK	TNIESE	0 7643	0.6331-0.9226	0.0717
Initial Initial <t< td=""><td>TNFSF13</td><td>APRIL CD256</td><td>TNESE</td><td>0.7978</td><td>0.6847-0.9296</td><td>0.0038</td></t<>	TNFSF13	APRIL CD256	TNESE	0.7978	0.6847-0.9296	0.0038
Initial Solution Display Initial Solution Display Display <thdisplay< th=""> Display Displa</thdisplay<>	TNFSF13B	BAFE CD257	TNESE	0.9889	0 8846-1 1056	0.8448
TNFSF15 TL1A TNFSF 0.9212 0.8391-1.0113 0.0848 TNFSF18 GITRL TNFSF 0.8992 0.7838-1.0316 0.1296 TNFSF4 OX-40L, CD134L, CD252 TNFSF 1.0323 0.9090-1.1723 0.6246 TNFSF8 CD30L, CD153 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-1BB-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNFSF14	LIGHT, HVEML, CD258	TNESE	1.0094	0.9061-1.1246	0.8648
TNFSF18 GITRL TNFSF 0.8992 0.7838-1.0316 0.1296 TNFSF4 OX-40L, CD134L, CD252 TNFSF 1.0323 0.9090-1.1723 0.6246 TNFSF8 CD30L, CD153 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-1B8-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNESE15	TI 1A	TNESE	0.9212	0.8391-1.0113	0.0848
TNFSF4 OX-40L, CD134L, CD252 TNFSF 1.0323 0.9090-1.1723 0.6246 TNFSF8 CD30L, CD153 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-1B8-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNFSF18	GITRL	TNFSF	0.8992	0.7838-1.0316	0.1296
TNFSF8 CD30L, CD153 TNFSF 0.8864 0.7979-0.9848 0.0247 TNFSF9 4-18B-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNFSF4	OX-40L, CD134L, CD252	TNFSF	1.0323	0.9090-1.1723	0.6246
TNFSF9 4-18B-L, CD137L TNFSF 1.0888 0.9787-1.2112 0.1177 VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNFSF8	CD30L, CD153	TNFSF	0.8864	0.7979-0.9848	0.0247
VTCN1 B7-H4 B7 0.9732 0.9192-1.0304 0.3513	TNFSF9	4-1BB-L, CD137L	TNFSF	1.0888	0.9787-1.2112	0.1177
	VTCN1	B7-H4	B7	0.9732	0.9192-1.0304	0.3513

TCGA, The Cancer Genome Atlas; HR, hazard ratio; CI, confidence interval.

expression, and Tumor Immune Dysfunction and Exclusion (TIDE) score. The TMB and neoantigen data of LUAD patients in the TCGA dataset were separated from The Cancer Immunome Atlas (TCIA) (https://tcia.at/home).²⁹ The protein data of PD-L1 expression was realized through the reverse-phase protein array (RPPA) analysis, which was retrieved from cbioPortal (http://www.cbioportal.org). TIDE has been proven to outperform known immunotherapy biomarkers in

predicting immunotherapy response in patients with melanoma and lung cancer, especially those treated with ICIs.³⁰ TIDE scores, T cell dysfunction scores, and T cell exclusion scores were download from the TIDE web (http://tide.dfci. harvard.edu) after following the instructions on the website to uploaded input data. All the expression details of these biomarkers used in this research are summarized in Supplementary Table 2.

Signature identification and statistical analysis

A univariate Cox proportional hazards regression analysis and stepwise Cox proportional hazards regression model were used to construct the signature. Then, the CMS was constructed using five selected genes (CD40LG, TNFRSF6B, TNFSF13, TNFRSF13C, and TNFRSF19) with a linear combination of their expression values. These inputs were weighted with the regression coefficients from the stepwise Cox regression analyses. The expression details of the five selected genes and the corresponding risk scores in different public cohorts are displayed in Supplementary Table 2. All the patients in different cohorts were divided into highand low-risk groups based on the optimal cutoff point, which was determined by the "surv_cutpoint" function of the "survminer" R package. The prognostic significance of the CMS between the high- and low-risk groups in different sets and subgroups were calculated with Kaplan-Meier curves and a 2-tailed log-rank test. The Mann-Whitney U-test was applied to analyze the between-group differences for immune cell fractions and immunotherapy biomarkers. Univariate and multivariate Cox regression analyses were conducted to clarify the independent prognostic factors. P < .05 was considered statistically significant for all statistical methods. STATA software (version 12.0) was used to perform the prognostic meta-analysis of CMS and B7-CD 28 signature. The two overall hazard ratio (HR) values were calculated using the random-effects model. R software version 3.5.1 (https://www.r-project.org) was used for other data analyses.

Results

The panorama and prognostic significance of costimulatory molecule genes in LUAD

A total of 60 costimulatory molecule genes were separated from the TCGA LUAD data, which consisted of 13 welldefined B7-CD28 family costimulatory molecules,¹³ and 47 TNF family costimulatory molecules (Table 1).¹⁶ The relationships of these molecules are shown in Supplementary Figure 1. Correlation analysis based on TCGA dataset

Table 2.	Clinical	characteristics	of the	enrolled	patients.
----------	----------	-----------------	--------	----------	-----------

revealed that most of the costimulatory molecules were highly relevant to others. Then, 502 LUAD patients with 60 costimulatory molecule expression data and matched complement OS information from the TCGA data were used to evaluate the prognostic significance of these candidate genes. Univariate cox proportional hazards regression analysis was conducted, and the results showed that 23 genes were significantly associated with OS (P < .05, Table 1). Among the significant genes, four genes (CD276, LTBR, TNFRSF1A and TNFRSF6B) were confirmed as risky factors with HRs (HR)>1, and 19 genes (CD27, CD28, CD40LG, CD80, CTLA4, EDA2R, ICOS, ICOSLG, LTA, LTB, TNFRSF10C, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF17, TNFRSF19, TNFSF12, TNFSF13 and TNFSF8) were confirmed as protective factors with HR<1.

Identification of CMS for prognostication

With the tremendous success in the clinical use of ICIs targeting costimulatory factors for lung cancer, we sought to establish CMS for prognostication. A stepwise Cox proportional hazards regression model was then used to filter out the redundant candidate genes and construct a prognostic model. Using the prognostic information of the 502 cases and the corresponding expression details of the 23 significant candidate genes, the stepwise method finally filtered out the combination of the 5 genes. We then developed a risk score formula for patients with LUAD based on the gene's expression levels to predict patient survival: risk score = $(-0.1075 \times \text{CD40LG}) +$ $(0.1418 \times$ TNFRSF6B) + $(-0.1603 \times$ TNFSF13) (-0.1069× TNFRSF13C) + (-0.0803× TNFRSF19). The expression panel of the five genes, the distribution of risk scores, and survival status of each patient are shown in Figure 1(a). Next, we classified all the patients in the TCGA cohort into high-risk (n = 292) and low-risk groups (n = 210) based on the optimal cutoff point (cutoff value = -2.3834). We found that patients in the high-risk group showed significantly worse OS (Figure 1 (b), HR 2.0435, 95% confidence interval (CI) 1.4811-2.8195, P < .0001). When we further applied the signature into different clinical stages, the results indicated that the formula still worked well. Specifically, we observed significant OS time

	TCGA	GSE1196	9	GSE19188	3	GSE31210		GSE41271		Independent
Characteristics	N=502	N=90	GSE13213 N=117	N=40	GSE30219 N=83	N=226	GSE37745 N=106	N=180	GSE50081 N=127	N=77
Age, year										
Mean	65.3	61.0	60.7	-	61.1	59.6	63.0	64.1	68.7	60.0
Gender										
Male	231	47	60	25	65	105	46	91	65	39
Female	271	43	57	15	18	121	60	89	62	38
Smoking history										
Yes	416	45	61	-	-	111	-	-	92	46
No	72	45	56	-	-	115	-	-	23	31
NA	14	0	0	-	-	0	-	-	12	0
TNM stage										
I and II	388	65	92	-	83	226	89	129	127	62
III and IV	105	25	25	-	0	0	17	51	0	15
NA	9	0	0	-	0	0	0	0	0	0
OS state										
Alive	320	50	68	16	40	191	29	111	76	57
Death	182	40	49	24	43	35	77	69	51	20

NA, not available; OS, overall survival.



Figure 1. Identification of the CMS in the TCGA dataset. (a) the distribution of risk score, survival status, and the five-gene expression panel. Kaplan-Meier curves were conducted to estimate overall survival for the high- and low-risk groups based on the risk score; (b) total patients with LUAD (c) patients with early-stage (stage I and II) LUAD. (d) patients with advanced-stage (stage III and IV) LUAD.

between the high- and low-risk groups both for early-stage (stage I and II) (Figure 1(c), HR 1.9961, 95% CI 1.3641–2.9210, P = .0003) and advanced stage disease (stage III and \Box) (Figure 1(d), HR 2.7529, 95% CI 1.6335–4.6394, P < .0001).

To further explore whether the signature-based risk score

was an independent factor in patients with LUAD, univariate,

and multivariate Cox regression analyses in the TCGA data-

base were conducted. The results of the multivariate Cox

regression model confirmed that the risk score was

a significant factor (HR = 1.7952, 95%CI 1.2254-2.6298,

P = .0027) independent of age, sex, smoking history, clinical

stage, and mutation (MUT) status (Table 3).

Evaluation of the performance of CMS in different clinical subgroups

Sex, age, smoking history, and MUT status were factors that influenced the TME, especially the expression of immune checkpoints. Consequently, patients from TCGA were then divided into different subgroups based on these parameters: sex (male or female), age [older (age \geq 60) or younger (age<60)], smoking (smoker or nonsmoker), and MUT status [EGFR wide-type (WT), EGFR MUT, KRAS WT, KRAS MUT, or EGFR/KRAS WT]. All the patients in different subgroups were stratified into high- and low- risk groups based on the risk

Table 3. Univariable and multivariabl	e Cox regression analysis o	f the costimulatory n	molecule-based signature and s	survival in TCGA dataset.
---------------------------------------	-----------------------------	-----------------------	--------------------------------	---------------------------

		Univariable analysis			Multivariable analysis	
Variable	HR	95%CI	P value	HR	95%CI	P value
Age						
≥60 or <60	1.1575	0.7957-1.6838	0.4445	1.3959	0.9490-2.0533	0.0903
Gender						
Male or Female	1.1568	0.8401-1.5928	0.3722	1.0080	0.7183-1.4145	0.9634
Smoking history						
Yes or No	1.0374	0.6532-1.6476	0.8763	1.0613	0.6366-1.7692	0.8195
T stage						
1, 2, 3 or 4	1.5458	1.2602-1.8961	<0.0001	1.2890	1.0171-1.6336	0.0357
Lymphatic metastasis						
Yes or No	2.4053	1.7466-3.3124	<0.0001	1.6992	1.1150-2.5897	0.0137
TNM stage						
I, II, III or IV	1.5587	1.3381-1.8156	<0.0001	1.1711	0.9242-1.4839	0.1912
ERFR status						
MUT or WT	1.4658	0.9584-2.2418	0.0777	1.4682	0.9181-2.3480	0.1089
KRAS status						
MUT or WT	1.2159	0.8598-1.7195	0.2689	1.2525	0.8706-1.8019	0.2250
Risk score						
High or low	2.1058	1.4571-3.0433	0.0001	1.7952	1.2254-2.6298	0.0027

Abbreviations: HR, hazard ratio; CI, confidence interval; WT, wild-type; MUT, mutation.

score with the same formula. The results showed that all the high-risk groups had significantly different OS compared to the paired low-risk groups (Supplementary Figures 2 and 3, P < .05).

Validation of the CMS in nine independent cohorts

To identify whether the CMS derived from the TCGA cohort was robust, we first evaluated its performance in eight independent public validation cohorts. These consisted of the remaining GSE11969, GSE13213, GSE19188, GSE30219, GSE31210, GSE37745, GSE41271, and GSE50081 datasets. The CMS stratified all patients from different public cohorts into the high- and low-risk groups using the same formula [risk $score = (-0.1075 \times CD40LG) +$ (0.1418× TNFRSF6B) + $(-0.1069 \times$ $(-0.1603 \times$ TNFSF13) + TNFRSF13C) (-0.0803× TNFRSF19)] with the optimal cutoff points. As shown in Figure 2, significant differences between the highand low-risk groups were found in most of the GEO datasets, including GSE13213 (cutoff value = -0.2261, HR 2.5990, 95% CI 1.3539-4.9890, P = .0029), GSE19188 (cutoff value = -0.0061, HR 2.4817, 95% CI 1.0571–5.8262, P = .0308), GSE30219 (cutoff value = -2.2083, HR 2.2955, 95% CI 1.1495-4.5839, P = .0156), GSE31210 (cutoff value = -2.5365, HR 2.2037, 95% CI 1.0960--4.4308, P = .0229), GSE41271 (cutoff value = -1.0183, HR 2.3023, 95% CI 1.4267-3.7153, P = .0004) and GSE50081 (cutoff value = -2.1254, HR 2.2958, 95% CI 1.2393-4.2530, P = .0066). Meanwhile, in the GSE11969 (cutoff value = 0.0607) and GSE37745 (cutoff value = -2.1263) datasets, the signature

showed a borderline difference between the high- and low-risk groups with P values of 0.1015 and 0.1192, respectively (Figure 2 (a and f)). The different performance of CMS in different datasets may be caused by the different race or the high spatial heterogeneity of the immune microenvironment.

To further measure whether the signature could be used in clinical practice, we validated the signature in an independent cohort that contained 77 frozen tissue samples with qRT-PCR data. By using the same model [risk score = $(-0.1075 \times \text{CD40LG})$ + $(0.1418 \times \text{TNFRSF6B})$ + $(-0.1603 \times \text{TNFSF13})$ + $(-0.1069 \times \text{TNFRSF13C})$ + $(-0.0803 \times \text{TNFRSF19})$] and the optimal cutoff point (cutoff value = -0.1300), patients were classified into high- (n = 32) and low-risk groups (n = 45). As expected, a significant difference in mortality was found between these two groups (Figure 2(i), HR 2.9189, 95% CI 1.1622–7.3309, P = .0169).

Compare the CMS with the previous model

Prior to the creation of our signature, Shanbo Zheng et al. constructed a signature for LUAD based on the costimulatory molecules from the B7-CD28 family (B7-CD28 signature) with a risk score of $0.3313 \times CD276 - 0.1559 \times CD28$.³¹ We then comprehensively assessed the prognostic significance of our CMS and the B7-CD28 signature by examining public datasets and conducting prognostic meta-analyses based on the nine groups (n = 1472) of the two different signature groups. As shown in Figure 3(a), our CMS performed very well in the different cohorts, producing HRs larger than 1. On the



Figure 2. The association between CMS and overall survival in nine different validation cohorts. Kaplan-Meier curves were created to estimate overall survival for in high- and low-risk groups based on the risk score. (a) GSE11969 (range from -0.0685 to 0.2331); (b) GSE13213 (range from -0.7562 to 0.5577); (c) GSE19188 (range from -0.2603 to 0.3283); (d) GSE30219 (range from -2.5093 to -1.5032); (e) GSE31210 (range from -2.9149 to -1.5841); (f) GSE37745 (range from -2.5732 to -1.6179); (g) GSE41271 (range from -1.8310 to -0.0865); (h) GSE50081 (range from -2.4230 to -1.4792); (i) an independent cohort with qPCR data.

contrary, the B7-CD28 signature was not that stable in different cohorts and some of the HRs were smaller than 1 (Figure 3(b)). More importantly, the meta-analysis combined HR of our CMS was far larger than that of the B7-CD28 signature. These findings indicate that our signature was superior to the previous model.

CMS related biological processes and pathways

The consistent prognostic performance of the CMS was confirmed in 10 different cohorts. This prompted us to investigate the biological features of patients with different risk scores. We first filtered out 2771 low-expression genes (genes where half or more than half of the values were 0) and then extracted the genes that strongly correlated with risk score (Pearson |R| >0.45, P < .0001) from the remaining 17759 genes in TCGA dataset. Collectively, 14 positively related genes and 399 negatively related genes were screened out (Figure 4(a)). Then, these selected genes were chosen for GO and KEGG analyses through

CMS-related immune cell infiltration and inflammatory activities

closely related to immune-specific pathways (Figure 4(c)).

use of the online DAVID tool (https://david.ncifcrf.gov). The

results revealed that signature-related genes were more

involved in the biological process of the immune response,

especially B cell and T cell-related immune response (Figure 4

(b)). KEGG analysis further confirmed that these genes were

To further increase our understating of the CMS-related immune landscape, we first explored the relationship between CMS and immune cell infiltration. The estimated fractions of different immune cells in the TME of LUAD were calculated by CIBERSORT, in combination with the LM22. The results demonstrated that the panorama of immune cells between high- and lowrisk patients were dramatically different (Figure 5(a)). In particular, high-risk patients showed a significantly higher proportion of activated NK cells, activated dendritic cells (DCs), neutrophils,



Figure 3. Compare CMS with previous costimulatory molecules signature. (a) a meta-analysis was performed using the prognostic results of CMS in nine public datasets. (b) a meta-analysis was performed using the prognostic results of the B7-CD28 signature in nine public datasets.



Figure 4. CMS-related biological pathways. (a) the most related genes of TNF family-based signature in patients with LUAD (Pearson |R| > 0.45, P < .0001). (b and c) GO and KEGG analyses of the related genes.

macrophages M0, resting DCs, and regulator T cells (Tregs) (Figure 5(b and c)). On the contrary, low-risk patients featured a high proportion of memory B cells, resting CD4 memory T cells, and gamma delta T cells (Figure 5(b and c)).

Next, to increase our understanding of CMS-related inflammatory activities, we assessed the relationship between CMS and seven clusters of metagenes. These consisted of 104 genes and represented different inflammation and immune response.³² The expression details of the collected genes and risk scores were displayed in Figure 5(d). Then, to explore the correlation between CMS and the entire metagenes of every cluster, the expression of corresponding gene clusters was calculated by Gene Sets Variation Analysis (GSVA).³³ Finally, the correlations were portrayed according to Pearson r-values between risk scores and metagenes (Figure 5(e)). The results revealed that CMS was negatively associated with HCK, LCK, MHC-I, and MHC-II. This indicated that patients with high CMS scores were characterized by an immune-suppressive state.

Association of CMS and immunotherapy response in patients with LUAD

Presently, immunotherapy is considered a first-line treatment for patients with LUAD. Costimulatory molecules are major candidates for immunotherapy. Therefore, we further assessed the association of CMS and immunotherapy response through analyzing the correlation of CMS and widely recognized immunotherapy biomarkers.³⁰ Totally, we enrolled eight indices, including TMB, the number of neoantigens, the number of clonal neoantigens, the number of subclonal neoantigens, the protein level of PD-L1, the TIDE score, the T cell dysfunction score, and the T cell exclusion score, to get a comprehensive evaluation. The results, as depicted in Figure 6, illustrated that high-risk patients were distinguished by a high level of TMB, neoantigens, protein level of the PD-L1 and T cell exclusion scores, and low level of the TIDE and T cell dysfunction scores. These results indicate that CMS-based high-risk patients may benefit from immunotherapy, especially ICIs.

Discussion

There is plenty of evidence pointing out that the immunosuppressive TME exhausts T cells and renders them anergic. This subsequently enables tumor cells to evade host immunemediated elimination.³⁴ Costimulatory molecules, especially the immune checkpoints, expressed on cancer cells or tumorinfiltrating lymphocytes play vital roles in regulating the antitumor immune response. Further, the blocking antibody targeting PD-L1/PD-1 has directly prolonged survival in patients with metastatic cancer.^{35,36} Presently, the costimulatory molecules mainly consist of two major families: the B7-CD28 family and the TNF family.³⁷ In this study, we simultaneously detected the expression pattern and clinical significance of 60 costimulatory molecules in patients with LUAD. Based on the significant genes, we developed a novel survival prediction model (CMS) based on the expression of five costimulatory molecular features in the TCGA dataset. The CMS score was



Figure 5. CMS-related immune cell infiltration and inflammatory activities. (a) the relative proportion of immune cell expression in high- and low-risk patients. (b and c) differentially expression immune cells in high- and low-risk patients. (d) the details of seven inflammatory metagenes and risk score. (e) correlogram of risk score, and inflammatory metagenes. *, **, ***, and **** represent P < .05, P < .01, P < .001 and P < .0001, respectively.



Figure 6. The expression pattern of immunotherapy response makers in high- and low-risk groups. The distribution of TMB (a), number of neoantigens (b), number of clonal neoantigens (c), number of subclonal neoantigens (d), protein level of PD-L1 (e), TIDE score (f), T cell dysfunction score (g) and T cell exclusion score (h) in high- and low-risk groups. *, **, ***, and **** represent P < .05, P < .01, P < .001 and P < .0001, respectively.

found as an independent risk factor for patients with LUAD. Furthermore, the CMS was well validated in eight different public GEO datasets and 77 cases from frozen tissues with qRT-PCR data. Interestingly, through prognostic metaanalysis, we proved that our CMS had better prognostic value than the previous costimulatory molecule-related signature. We also explored the immune panorama – including immune cell distribution and inflammatory activities – in CMS highand low-risk patients. Additionally, we found that the CMS score was positively related to different immunotherapy biomarkers. To our knowledge, this is the first and most comprehensive study to date to describe the prognostic and immunotherapy response prediction value of a CMS in patients with LUAD.

To get the whole picture of costimulatory molecule expression in patients with LUAD, we collected the 13 members from the B7-CD28 family and the 47 members from the TNF family into our analysis.^{13,16} After the univariate Cox proportional hazards regression analysis and stepwise Cox proportional hazards regression model, we found that all five selected genes (CD40LG, TNFRSF6B, TNFSF13, TNFRSF13C, and TNFRSF19) belonged to the TNF family. This indicated that costimulatory signals and pathways in the TNF family had a more important prognostic value than those in the B7-CD28 family in patients with LUAD. CD40LG - also known as CD40L, TNFSF5, or CD154 - is a membrane-bound protein belonging to the TNFSF family. CD40LG has been a therapy target in cancer treatment because of its ability to trigger Th1-type immune responses.³⁸ The expression and prognostic states of the CD40LG-CD40 axis was previously reported in lung cancer.³⁹ TNFRSF6B, a soluble decoy receptor, is also known as Decoy receptor 3 (DcR3), belongs to the TNFRSF family.⁴⁰ TNFRSF6B inhibits apoptosis and promotes angiogenesis through binding with FASL, LIGHT, and TL1A.41,42 Moreover, studies found that DcR3 is a potential immunotherapy target for cancer treatment.43 TNFSF13, also known as APRIL and CD256, is a proliferation-inducing ligand that plays an important role in B cell development.⁴⁴

The clinical significance of TNFSF13 in several cancers was previously revealed and included NSCLC,45 breast cancer,46 B-cell chronic lymphocytic leukemia,⁴⁷ and other tumor types. TNFRSF13C (BAFFR or CD268), a receptor of BAFF, is a crucial regulatory factor in B cell proliferation, development, and maturation.⁴⁸ Hong Qin et al. reported that a novel anti-BAFFR antibody may be a promising strategy for drugresistant B-cell malignancies.49 TNFRSF19, also known as TROY or TAJ, is a member of the TNFRSF family and demonstrates complex and pleiotropic functions in different cellular contexts.⁵⁰ Present evidence displayed that TNFRSF19 acted as a tumor suppressor in patients with lung cancer.⁵¹ Although the expression details of these five members in various cancer types have been described, the combination and functions of these molecules still warrants further exploration.

To verify the robustness of CMS, we reproduce the model in nine different cohorts, and the significance of CMS was finally confirmed by prognosis meta-analysis. It is worth mentioning that the number of validation cohorts in our research was larger than that of any other studies in the LUAD population. This made our signature more reliable and clinically feasible. Before our study, a signature based on the expression of costimulatory molecules from the B7-CD28 family was constructed.³¹ Through meta-analysis, we obtained two crucial conclusions: the CMS signature had prognostic significance across these public datasets, although some of the P-values were not statistically significant and our CMS model demonstrated an advantage over the reported B7-CD28 model. These conclusions are consistent with our finding that the TNF family has a more important prognostic value for patients with LUAD.

Through analysis, the most related genes of CMS, the potential mechanisms of CMS in LUAD was proved to be closely associated with the immune-related process. Hence, the details of CMS-specific immune profiles were further analyzed. We found that there were higher proportions of DCs, NKs, and Tregs in CMS high-risk patients TME. Simultaneously, inflammatory metagene analysis revealed that CMS score was negatively related to monocyte/myeloid lineage- and T cell-specific functions (HCK and LCK). What's more, CMS score was also found negatively related to the antigen-presenting process of T cells (MHC-I and MHC-II) in LUAD. Thus, CMS high-risk patients appear to exhibit a high immune cell infiltration microenvironment while in an immune-suppressive state.

Interestingly, this research highlighted the potential role of CMS in predicting the response to immunotherapy in patients with LUAD. Because the immune checkpoint targets (PD-L1 and PD-1) are costimulatory molecules, CMS may have the ability to predict the response to ICIs-based immunotherapy. Due to the lack of details regarding mRNA expression in cases with immunotherapy, we had to evaluate the relationship indirectly. We collected TMB, the number of neoantigens, the protein level of PD-L1, and the TIDE scores. TMB is one of the classic biomarkers for immunotherapy response, and neoantigen burden is always increased by TMB. This will be useful for T cell recognition.^{52,53} The PD-L1 expression level was another well-known biomarker for ICIs in lung cancer.54 The TIDE score is a newly-developed method for immunotherapy response prediction, and considered a more accurate biomarker than TMB or PD-L1 expression.³⁰ Collectively, high-risk patients exhibited high TMB and PD-L1 expression. From a mechanical standpoint, this resonated with the results of the immune profile analysis. By comparing the CMS scores with these different verified biomarkers, we preliminarily speculate that CMS high-risk patients may be suitable for immunotherapy. These findings give us additional confidence that the CMS scores may act as a novel predictive biomarker for immunotherapy response.

There are some limitations to this study that warrant consideration. Firstly, although we tried our best to include as many independent datasets as possible for validation, this study was retrospective. Secondly, the CMS-specific immune landscape was realized through bioinformatic methods with RNA-seq data. This analysis may have been influenced by noise. Thirdly, because the mRNA expression data from patients with immunotherapy was not available, the prediction ability of CMS for immunotherapy response was estimated indirectly. Future prospective studies could affirm the complete prediction ability and a molecular picture of the CMS signature.

Conclusions

Here, we have performed a first costimulatory molecule landscape analysis in patients with LUAD. We built a reliable, clinically feasible prognostic signature named CMS and identified the potential underlying immune-related mechanisms of this signature. Importantly, the CMS was tightly related to well validated immunotherapy biomarkers. Thus, the CMS could be a clinically useful tool for prognostic management and predicting immunotherapy response in patients with LUAD. Future validation of the predictive capability of this formula will be helpful for patients seeking counseling and individualized treatment.

List of abbreviations

NSCLC	non-small cell lung cancer
LUAD	lung adenocarcinoma
OS	overall survival
ICIs	immune checkpoint inhibitors
PD-1	programmed cell death protein 1
PD-L1	programmed cell death 1 ligand 1
TME	tumor microenvironment
TCR	T cell receptor
TNF	tumor necrosis factor
TNFSF	TNF ligands superfamily
TNFRSF	TNF receptors superfamily
TCGA	The Cancer Genome Atlas
CMS	costimulatory molecule-based signature
GEO	Gene Expression Omnibus
UCSC	University of California Santa Cruz
qPCR	quantitative real-time polymerase chain reaction
GO	gene ontology
KEGG	Kyoto Encyclopedia of Genes and Genomes
NKs	natural killer cells
ТМВ	tumor mutation burden
TIDE	Tumor Immune Dysfunction and Exclusion
TCIA	The Cancer Immunome Atlas
RPPA	the reverse phase protein array
HR	hazard ratio
CI	confidence interval
WT	wild-type
MUT	mutation
DCs	dendritic cells
Tregs	T cells regulatory
GSVA	Gene Sets Variation Analysis
DcR3	Decoy Receptor 3

Acknowledgments

All authors would like to thank the specimen donors and research groups for TCGA, GSE11969, GSE13213, GSE19188, GSE30219, GSE31210, GSE37745, GSE41271, and GSE50081 that provided data for this collection.

Availability of data and materials

All the GEO cohorts were downloaded for GEO datasets database with processed series matrix files. Specifically, GSE11969 (https://ftp.ncbi.nlm. nih.gov/geo/series/GSE11nnn/GSE11969/matrix/), GSE13213 (https://ftp. ncbi.nlm.nih.gov/geo/series/GSE13nnn/GSE13213/matrix/), GSE19188 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE19nnn/GSE19188/matrix/), GSE30219 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE30219/matrix/), GSE31210 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE31210/matrix/), GSE31210 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE31210/matrix/), GSE37745 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE31nnn/GSE37745/matrix/), GSE41271 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE30nnn/GSE37745/matrix/), and GSE50081 (https://ftp.ncbi.nlm.nih.gov/geo/series/GSE50081/matrix/). The other data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure of Potential Conflicts of Interest

The authors declare that they have no competing interests.

Funding

This work was supported by the National Key R&D Program of China under Grant under Grant 2017YFC0907903; the CAMS Innovation Fund for Medical Sciences under Grant 2017-I2M-1-005 and 2016-I2M-1-001); the National Key R&D Program of China under Grant 2016YFC1303201, the National Natural Science Foundation of China under Grant 81802299 and 81502514, the Fundamental Research Funds for the Central Universities under Grant 3332018070, and the National Key Basic Research Development Plan under Grant 2018YFC1312105

References

- 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
- 3. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong -K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546. doi:10.1038/nrc3775.
- Herbst RS, Baas P, Kim DW, Felip E, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England). 2016;387:1540–1550. doi:10.1016/S0140-6736(15)01281-7.
- Borghaei H, Paz-Ares L, Horn L, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774.
- Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja M-K, Yu X-Z, Dong C. T-cell tolerance or function is determined by combinatorial costimulatory signals. Embo J. 2006;25 (11):2623–2633. doi:10.1038/sj.emboj.7601146.
- Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223–229. doi:10.1016/j.drudis.2019.11.003.
- 9. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995;2:555–559. doi:10.1016/1074-7613(95)90000-4.
- Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res Ther. 2008;10(Suppl 1):S3. doi:10.1186/ar2414.
- 11. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2019;176:677. doi:10.1016/j.cell.2019.01.008.
- Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–182. doi:10.1111/j.1600-065X.2008.00662.x.
- 13. Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology. 2015;4:e1026534.
- 14. Zhang C, Zhang Z, Li F, Shen Z, Qiao Y, Li L, Liu S, Song M, Zhao X, Ren F, et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Oncoimmunology. 2018;7(11):e1461304. doi:10.1080/2162402X.2018.1461304.
- Ward-Kavanagh LK, Lin WW, Sedy JR, Ware C. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity. 2016;44(5):1005–1019. doi:10.1016/j. immuni.2016.04.019.
- 16. Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune

system and beyond. Physiol Rev. 2019;99(1):115–160. doi:10.1152/physrev.00045.2017.

- Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147–168. doi:10.1038/nrd3930.
- Schildberg FA, Klein SR, Freeman GJ, Sharpe A. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955–972. doi:10.1016/j.immuni.2016.05.002.
- 19. Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–16.e11.
- Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J clin oncol. 2006;24:1679–1688. doi:10.1200/ JCO.2005.03.8224.
- Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, Yatabe Y, Takahashi T. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J clin oncol. 2009;27(17):2793–2799. doi:10.1200/ JCO.2008.19.7053.
- 22. Hou J, Aerts J, den Hamer B, van IJcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS One. 2010;5(4):e10312. doi:10.1371/journal.pone.0010312.
- 23. Rousseaux S, Debernardi A, Jacquiau B, Vitte A-L, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon P-Y, Lantuejoul S, Hainaut P, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5 (186):186ra66. doi:10.1126/scitranslmed.3005723.
- Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ ALK-negative lung adenocarcinomas. Cancer Res. 2012;72 (1):100–111. doi:10.1158/0008-5472.CAN-11-1403.
- Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Ponten F, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19(1):194–204. doi:10.1158/1078-0432.CCR-12-1139.
- 26. Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013;11(6):638–650. doi:10.1158/1541-7786.MCR-12-0634-T.
- 27. Der SD, Sykes J, Pintilie M, Zhu C-Q, Strumpf D, Liu N, Jurisica I, Shepherd FA, Tsao M-S. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thoracic Oncol. 2014;9(1):59–64. doi:10.1097/JTO.00000000000042.
- Newman AM, Liu CL, Green MR, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2012;72:100–111. doi:10.1038/nmeth.3337.
- 29. Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
- 30. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24 (10):1550–1558. doi:10.1038/s41591-018-0136-1.
- Zheng S, Luo X, Dong C, Zheng D, Xie J, Zhuge L, Sun Y, Chen H. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. Int J Cancer. 2018;143(10):2592–2601. doi:10.1002/ijc.31764.

- 32. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11(2):R15. doi:10.1186/bcr2234.
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
- Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–682. doi:10.1038/nri3902.
- Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science (New York, NY). 2020;367(6477):eaax0182.
- 37. Tang J, Jiang W, Liu D, Luo J, Wu X, Pan Z, Ding P, Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018;7(10):e1488566. doi:10.1080/ 2162402X.2018.1488566.
- Xu W, Li Y, Yuan WW, Yin Y, Song -W-W, Wang Y, Huang -Q-Q, Zhao W-H, Wu J-Q. Membrane-Bound CD40L promotes senescence and initiates senescence-associated secretory phenotype via NF-kappaB activation in lung adenocarcinoma. Cell Physiol Biochem. 2018;48(4):1793–1803. doi:10.1159/000492352.
- Mu CY, Qin PX, Qu QX, Chen C, Huang JA. Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis. Chronic Dis Transl Med. 2015;1:36–41. doi:10.1016/j.cdtm.2015.02.010.
- Lin S, Wu B, Lin Y, Wang M, Zhu Y, Jiang J, Zhang L, Lin J. Expression and clinical significance of decoy receptor 3 in acute-on-chronic liver failure. Biomed Res Int. 2019;2019:9145736. doi:10.1155/2019/9145736.
- 41. Lin WW, Hsieh SL, Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011;81:838–847. doi:10.1016/j.bcp.2011.01.011.
- Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem. 1999;274:13733–13736.
- Hsieh S-L, Lin -W-W. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. J Biomed Sci. 2017;24(1):39. doi:10.1186/s12929-017-0347-7.
- 44. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263–275. doi:10.1016/j.smim.2006.04.006.

- 45. Sun B, Wang H, Wang X, Huang H, Ding W, Jing R, Shi G, Zhu L. A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res. 2009;35(6):486–500. doi:10.1080/ 01902140902759274.
- 46. Pelekanou V, Kampa M, Kafousi M, Darivianaki K, Sanidas E, Tsiftsis DD, Stathopoulos EN, Tsapis A, Castanas E. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer. 2008;8(1):76. doi:10.1186/1471-2407-8-76.
- 47. Bojarska-Junak A, Hus I, Chocholska S, Wąsik-Szczepanek E, Sieklucka M, Dmoszyńska A, Roliński J. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33(10):1319–1327. doi:10.1016/j.leukres.2009.03.030.
- 48. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B Cell Maturation in Mice Lacking BLyS Immunity. 2001;15:289–302.
- 49. Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, et al. Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug-resistant human B-cell malignancies in vivo. Clin Cancer Res. 2018;24(5):1114–1123. doi:10.1158/1078-0432.CCR-17-1193.
- Eby MT, Jasmin A, Kumar A, Sharma K, Chaudhary PM. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. J Biol Chem. 2000;275 (20):15336–15342. doi:10.1074/jbc.275.20.15336.
- 51. Shao L, Zuo X, Yang Y, Zhang Y, Yang N, Shen B, Wang J, Wang X, Li R, Jin G, et al. The inherited variations of a p53-responsive enhancer in 13q12.12. Confer Lung Cancer Risk by Attenuating TNFRSF19 Expression Genome Biology. 2019;20:103.
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348 (6230):124–128. doi:10.1126/science.aaa1348.
- 53. Gong Z, Jia Q, Chen J, Diao X, Gao J, Wang X, Zhu B. Impaired cytolytic activity and loss of clonal neoantigens in elderly patients with lung adenocarcinoma. J Thoracic Oncol. 2019;14(5):857–866. doi:10.1016/j.jtho.2019.01.024.
- 54. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011.